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OSTEOSARCOMA  
Osteosarcoma (OS) is a highly malignant mesenchymal tumor of bone in which the malignant 
cells produce osteoid (1). It is one of the most common primary, non-hematologic bone 
malignancies in children that occurs most frequently in patients between the ages of 10 and 25 
years (2). Before the advent of multi-agent chemotherapy, amputation provided a long-term 
survival rate of about 20%. The use of multi-agent chemotherapy combined with aggressive 
surgery has improved the long-term survival in these patients to approximately 60% 
(3).Interestingly, survival of patients treated with chemotherapy alone is only 20%, suggesting 
that populations of tumor cells in a large percentage of osteosarcomas are highly resistant to 
chemotherapy. Despite intensive efforts in both surgical and medical management, the 
survival rate has not improved over the last 30 years and fully 40% of osteosarcoma patients 
die of their disease. Osteosarcoma can arise in any bone, but occurs primarily in the juxta-
epiphyseal regions of rapidly growing long bones (Fig.1). 
 
Fig.1. Radiographic appearance of osteosarcoma of the knee. (http://www.mypacs.net) 
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Osteosarcoma often begins as a process destructive of medullary bone that progresses to 
destroy cortical bone, usually with an associated soft-tissue component. The histopathologic 
appearance of high-grade intramedullary osteosarcoma is one of malignant spindle cells 
producing osteoid and immature bone. Cytogenetic evaluation has revealed numerous 
complex chromosomal abnormalities that change both within and between individual tumors 
in osteosarcoma (4). Molecular analyses have revealed a variety of genetic alterations in 
osteosarcoma, including inactivation of p53 and retinoblastoma tumor suppressor genes, 
downreguation of INK4α and overexpression of oncogenes such as MDM2 (5). For example, 
alterations of the retinoblastoma gene (RB1) have been shown in up to 70% of reported cases, 
and loss of heterozygosity for RB1 has been shown to be a marker of poor prognosis (6). 
Moreover, the gene INK4α, that encodes for  negative regulators of cell cycle p16 and p14, is 
deleted in 10% of OS (7) and their protein products are considered biomarker of survival in 
patients with osteosarcoma (8). Major signaling pathway alterations also have been 
implicated, such as the pathway of Wnt, that has been associated  with metastasis and poor 
prognosis (9). Abnormal expression of growth factors, such as TGF-b3, also has been 
associated with poor outcome. The use of novel effective therapeutic approaches and 
treatment strategies in patients who are resistant to current therapy could provide an 
improvement in outcome in patients.  Improvements in outcome in paediatric OS have been 
achieved without the addition of novel agents, but rather through optimization of the dose, 
combination, schedule, and duration of treatment using standard systemic chemotherapy. 
Over the last decade, technological advances in research and medicine have provided detailed 
descriptions of factors that contribute to the malignant phenotype of this disease with the hope 
of finding new therapeutic treatments and strategies (10). Most of the phase III of clinical 
trials are combination treatments of conventional chemotherapy agents (11). OS overexpress 
several receptor tyrosine kinases (RTKs) including ErbB2, IGF-1R, PDGFR, VEGFR, and 
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activate the downstream signal-transduction pathways. Using of multi-RTKs in OS may be a 
powerful tool for the outcome of these tumors (12). Many tyrosine kinase inhibitors have 
been preclinically and clinically evaluated for OS desease, such as Imatinib and Dasatinib. 
Ongoing trials include the phase I/II study of dasatinib in combination with ifosfamide, 
carboplatin, and etoposide in young patients with metastatic or recurrent malignant solid 
tumors, including OS (10). The vascular endothelial growth factor (VEGF) pathway is 
involved in angiogenesis and is crucial for tumor growth and progression. It presents three 
isofroms, (VEGFR-1, -2, and -3) of which OS cell lines express the isoform VEGFR-3, that 
has been associated with poor survival (13). Cediranib (AZD 2171), sorafenib, and sunitinib. 
Combination of cediranib with the EGFR inhibitor gefitinib were tested in a phase I trial in 
patients with advanced solid tumors and demonstrated positive response in one OS patient 
(14). The insulin-like growth factor-1 receptor (IGF-1R) 1R has been implicated in the 
development of sarcomas and inhibition of its function has been demonstrated to reduce 
growth in OS (15). More than 25 antibodies and small molecules that specifically inhibit IGF-
1R have undergone preclinical and clinical testing in both adults and children alone (16,17). 
However, despite clear evidence of clinical benefits in some pediatric patients, several drug 
companies have curtailed or eliminated anti-IGF-1R programs because the observed clinical 
benefits of targeting this pathway in single and multi-agent strategies did not met the primary 
endpoints in many adult trials. The current development of anti-IGF-1R therapy is being 
reviewed.  
 Activation of the mTOR pathway is implicated in the development and progression of OS 
(18) which makes mTOR an appealing target for therapeutic intervention. Rapamycin 
(sirolimus) and rapalogs (everolimus, temsirolimus, and ridaforolimus) are 
immunosuppressive macrocyclic lactone antibiotics that inhibit the kinase activity of 
mTORC1 while mTORC2 is generally rapamycin- insensitive (19). The response to these 
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compounds alone or in combination with other has been tested in preclinical and clinical trials 
(20, 21, 22, 23, 24) without a really good results. Novel small-molecule inhibitors that are 
mTOR-selective or dual mTOR/PI3K inhibitors have entered clinical trials. A key focus in the 
development of these drugs will be to establish the effectiveness of combination strategies 
with other targeted therapies and standard cytotoxic agents. IGF-1R signals through Akt and 
is suggested to be involved in resistance to mTOR inhibitors. Combined inhibition of IGF-1R 
and mTOR has been evaluated. Antibodies targeting IGF-1R (R1507, figitumumab, 
cixutumumab) in combination with rapamycin and rapalogs showed enhanced activity 
compared to the single agents (25, 26, 27). Further use of mTOR inhibitors in the treatment of 
OS patients is under investigation as single-dose therapy and multi-agent therapy in order to 
determine effective dosing schedules and additive combinations. PI3K and Akt activation 
may drive tumorigenesis in OS by regulating effectors that are different from mTORC1. 
Inhibition of Akt signaling reduces tumor survival and enhance the effectiveness of cytotoxic 
chemotherapy by increasing apoptosis (28, 29). The development of specific inhibitors of 
PI3K/Akt pathway is under investigation. Many growth factor receptors associated with the 
biology of OS (IGF-1R, EGFR,VEGFR, and PDGFR) activate the MAPK/ERK pathway to 
make it a powerful target for therapeutic intervention. AZD6244 is a potent and specific 
inhibitor for MEK 1/2 and demonstrated effective tumor growth inhibition of OS (30). 
Cyclin-dependent kinases regulate orderly progression through the cell cycle. The use of 
inhibitors of cdks activity, such as seliciclib, alvocidib and dinaciclib induces cell cycle arrest 
and apoptosis of several OS cell lines (31) . Mutations in p53 (32) and amplification of 
MDM2 have been reported in OS (33). Antagonist of MDM2 and inhibitor of MDM2/p53 
axis are under investigation (34, 35). Histone deacetylases (HDACs) regulate acetylation of 
histone lysine residues which triggers transcriptional activity promoting cell transformation 
and proliferation. Deregulation of histone acetylation is associated with disease pathogenesis 
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by promoting alterations in chromatin structure and gene transcription. HDAC inhibitors 
induce growth arrest and cell death by epigenetic changes in many preclinical and clinical 
cancer models (10). During programmed cell death, Smac, an endogenous pro-apoptotic 
protein of the mitochondria is released and promotes apoptosis via inhibition or proteasomal 
degradation of the inhibitor of apoptosis (IAP) family of proteins. Overexpression of Smac 
has been shown to sensitize OS cells in vitro to chemotherapeutic drug-induced apoptosis 
(36). Thus, the use of small-molecule drugs that act as Smac mimetics in OS cells that 
overexpress IAP might be a potent strategy to elicit a pro-apoptotic anti-cancer response (37). 
LCL161 demonstrated tumor growth delay in five of six OS xenografts and intermediate 
activity in one xenograft in the PPTP (37). The future application of small-molecule Smac 
mimetics as a treatment for OS warrants further investigation in multi-agent therapies with 
chemotherapy or other targeted therapies inclusive of agents that target apoptosis. The 
identification of new therapeutic drugs using strategies which target cell proliferation (multi-
tyrosine kinase receptor inhibitors), angiogenesis (VEGF inhibitors), apoptosis, and DNA 
cytotoxicity in combination with standard chemotherapy has demonstrated promise in 
preclinical and early-phase clinical trials for OS (10). The emergence of numerous anti-cancer 
agents and the small number of OS patients eligible for early-phase clinical trials present 
another challenge in the clinical testing of novel compounds. The systematic preclinical 
evaluation of new agents in paediatric cancer has received huge support by the efforts of the 
Pediatric Pharmacoepidemiology Training Program (PPTP) supported by National Cancer 
Institute (NCI) (38). Since 2007, this program has facilitated the comprehensive analysis of 
more than 50 novel and standard agents in in vitro and in vivo panels of childhood cancers. 
The PPTP has demonstrated that OS xenografts provide a rapid and efficient platform to test 
new therapies for anti-tumor effects, offering a link between preclinical and clinical testing 
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with the potential of benefits to paediatric patients (10). In figure 2 the most important targets 
and therapies above discussed are shown. 
 
Fig.2. Targets and therapies in preclinical and clinical development in children and adolescent bone 
sarcomas. The different colours described the current clinical development of the drugs. (Red) Preclinical; 
(Orange) Phase I; (Blue) Phase II; (Green) Phase III(all in pediatric studies); (Black) Phase I or II in adults: all 
solid tumours (http://www.hindawi.com/journals/sarcoma/2012/301975). 
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CANCER STEM CELLS (CSCs) 
 
Tumor microenvironment plays an important role in cell behavior and tumorigenesis. This 
network consists of different cell populations with normal and tumor cells in contact  to each 
other. Within a tumor, only a minor subset of tumor cells are able to proliferate and divide 
unlimitedly to generate the tumor mass. This sub-population is defined as cancer stem cells 
(CSCs) (39).  The name “CSCs” refer to the fact that they share many properties with normal 
stem cells (SCs), including activation of main cell signalling pathways such as Wnt, Notch, 
Hedgehog and others. Deregulation of some of these important signalling pathways in CSCs 
is involved in tumorigenesis (40, 41). CSCs behave like normal stem cells in many other 
aspects such as multipotency, membrane transport, DNA repair and the ability to regulate 
self-renewal, differentiate in response to oncogenic mutations and external stimulations, drug 
resistance (Fig.3). 
 
Fig.3. Features of cancer stem cells (CSCs) and tissue stem cells (SC) (Cancer Stem Cells lab- 
http://kirshner.bio.purdue.edu/ 
 
In cell culture, animal models and cancer patients it has been observed that these cells are 
responsible for cancer therapy failure using several molecular mechanisms, including 
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apoptosis resistance, drug-efflux pumps, enhanced DNA repair efficiency, detoxification 
enzyme expression and quiescence (42) For instance, in breast and AML (acute  myeloid 
leukemia) CSCs, BCL2 and BCLXL are highly expressed (43, 44). Similarly, in primary 
GBM (glioblastoma) cultures CD133+ CSCs have elevated expression of BCL2 and BCLXL 
compared to their more differentiated CD133-progeny (45). Besides an elevated apoptotic 
threshold, CSCs display high expression of drug efflux pumps, like ATP-binding cassette 
(ABC) transporter family proteins (42), important for efflux of chemotherapy across the 
plasma membrane. Various ABC transporter proteins are highly expressed in hematopoietic 
stem cells (HSC) and in AML CSCs (CD34+/CD38-) compared to the non-stem 
(CD34+/CD38+) cells (46). Also in GBM and melanoma high expression of drug efflux 
pumps in CSCs are reported (47). A recent observation is that CSCs may display quiescent 
properties to escape the selectivity of classical chemotherapy for cancer cells that are highly 
proliferative (42). Quiescent cells not only affects chemotherapy sensitivity, but also have a 
high DNA repair activity through an increased expression of DNA repair genes, such as 
ATM, ATR and Wee1 (42). Many chemotherapeutic agents and radiotherapy work by 
inducing DNA damage and cells that effectively repair DNA damage, such as CSCs, can 
potentially survive to therapeutic treatment. Various reports have shown that CSCs, such as 
GBM and  breast CSCs, present high DNA repair activity, which makes them resistant to 
radiation and chemotherapy (48). In conclusion, there are many ways for CSCs to resist tumor 
therapy. Figure 2 illustrates the reasons for therapy resistance in CSCs (Fig.4). 
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Fig.4. Main mechanisms of CSCs theraphy resistance. (Medicine-Oncology, book edited by Juan Manuel 
Mejia- Arangure, ISBN 978-953-51-0990-7, Published: April 17, 2013 under CC BY 3.0 license; Dong W, Zhu 
H et al; DOI: 105.5772/55075) 
 
CSCs are characterized by the presence of several cell surface markers, such as CD133, 
CD44, CD13, CXCR1, Lgr5 and others. Identification of CSC markers and their roles in 
molecular mechanisms of tumorigenesis is critical to understanding tumor cell behavior in the 
tumor microenvironment and the development of new therapeutic modalities. Specific cell 
surface markers can help to identify, isolate and characterize both normal and cancer stem 
cells (39). Various groups and companies developed immunotoxins that directly target CSC 
markers. For instance, they produced antibodies against the stem cell marker CD133 
conjugated to paclitaxel or cytolethal distending toxin (Cdt) target cells expressing CD133 
and show in vitro and in vivo elimination of tumors (49, 50). However, CD133 expression is 
also expressed in normal stem cells surface, which should be protected from such therapies at 
all times. To minimize toxicity and deliver drug to cancer selectivity, photochemical 
internalization (PCI) has been developed. With this technique is possible to release drug in the 
tumor area specifically (51). Antibodies without toxins targeting other cell surface molecules 
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are shown to be efficient in killing CSCs as well. For example, antibodies against CD47 gave 
promising effects in various cancers. CD47 is a receptor that is involved in inhibition of 
phagocytosis signals and is highly expressed on CSCs compared to more differentiated cells. 
The block of this CD47 receptor affects phagocytosis  of AML CSCs and thereby blocks 
tumor growth. In addition, it has been showed that CD47 inhibition blocks tumor growth in 
solid cancers like breast cancer, CRC, ovarian cancer and GBM (52, 53). Moreover, several 
antibodies have shown to delete essential signals from CSCs. For instance, direct targeting of 
breast CSCs can be achieved by using an antibody against CXCR1. The IL8 receptor CXCR1 
is expressed almost exclusively on CSCs and Repertaxin, an inhibitor of CXCR1/2, or anti-
CXCR1 treatment induces cell death in CXCR1+ breast CSCs, which appears to be mediated 
by AKT signaling inhibition (42). As described, CSCs require signaling pathways for their 
maintenance, suggesting that these may be attractive targets for therapy.  For this reason, 
several compounds have been synthesized, such as Salinomycin, CUR199691 and DLL4, that 
inhibit Wint, Hedgeog and Notch pathways respectively (54, 55, 56). Antibodies can also 
target the CSC niche. For example, it has been observed that the use of Bevacizumab, an 
antibody against VEGF, induce GBM CSCs differentiation (57). In 2006 Jin et al. showed 
that using an antibody against CD44 decreased homing of AML cells and thereby promoting 
the AML CSCs to differentiate cancer cell progeny. This antibody also inhibited AML growth 
in mice (58). Another mechanism to target CSCs is to induce their differentiation by using 
specific protein, such as BMP4 (bone morphogenic protein 4) that induces GMB CSCs 
differentiation and inhibits their tumorigenicity (59). Altogether, direct CSCs targeting or 
CSCs differentiation induction are promising in the development of new tumor therapies, 
even if studies are needed to investigate the best combination treatments that does not give 
severe toxicities. Figure 5 describes the different effects between classical cancer therapies 
and CSCs specific therapies. 
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Fig.5. Traditional cancer therapies and CSCs specific therapies effects. (www.magrogenics.com/platform-
cancer_stem_cells_csc.html) 
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P53 
P53 is a tetrameric transcription factor consisting of three structural and functional domains: 
the amino-terminal transcriptional activation domain (TAD, residues 1–42); the DNA binding 
domain (DBD, aminoacidic residues 101–306); the carboxyl-terminal oligomerization domain 
(OD, residues 307–355) (Fig.6).  
 
Fig.6. Structural organization of TP53 gene and p53 protein. (St. Jude Children’s Research Hospital-website) 
  
The protein p53 is normally kept at low expression levels through ubiquitylation and  
proteasomal degradation, mediated by several E3 ubiquitin ligase and MDM2 and MDM4 
(60). P53 turnover is controlled by the association of MDM2, MDM4, HAUSP (herpesvirus-
associated ubiquitin-specific protease) and the adaptor protein DAXX (61, 62, 63, 64, 65) 
(Fig.7).  HAUSP can deubiquitylate both MDM2 and p53. Under normal condition DAXX 
guides it towards MDM2 and MDM4. This minimize MDM2 auto-ubiquitylation and 
promotes p53 ubiquitylation and turnover. 
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Fig.7. Mechanism of p53 turnover 
 
P53 is activated in response of cellular stresses, including DNA damage and 
hyperproliferation (66). Once induced, p53 regulates the expression of a wide range of genes, 
leading to the biological outcomes of repair, growth arrest, senescence or apoptosis (67) 
(Fig.8).  
 
Fig.8. Activation of transcription by p53 wild type. Stress signals, such as DNA damage and activation of 
oncogenes, cause post-translational modifications of p53, mediated by interaction with stress-sensing molecules 
like Tip60, ATM and PIN1. Once activated, p53 can induce cell cycle arrest, senescence and apoptosis through 
transcriptional regulation of its target genes. 
 
Upon these stress signals, p53 leads post-translational modifications such as phosphorylation, 
acetylation, sumoylation, ubiquitination (68) through the interaction with stress-sensing 
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molecules like TAT Interacting Protein 60 (Tip60) (69), Ataxia Telangiectasia Mutant 
(ATM), Rad-3 related protein kinase (ATR) and Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1 (PIN1) (70, 71). These interaction determine the destruction of MDM2-DAXX-
HAUSP complex and the rapid destruction of MDM2 and MDM4 with a consequent 
accumulation of stable p53 (72) (Fig.7). 
 More than half of all human cancers carry p53 gene mutations that can be divided 
empirically into three functionally non-exclusive categories: Loss of function, gain of 
function (GOF) mutations and dominant negative mutations (73).The first one are responsible 
for the loss of the tumor suppressor function of p53 and usually they are defective in 
sequence-specific transactivation of genes containing wild type (WT) p53 consensus binding 
sites. Most of these p53 mutations are missense mutations, mainly located within the DNA 
binding domain, that generate stable p53 proteins unable to bind canonical p53 consensus 
sequences (74). There are two classes of mutant p53. Class I mutants (e.g. mutants at codons 
248 or 273) are characterized by an alteration in the residues which determine a sequence-
specific binding to the DNA. Class II mutants (e.g. mutants at codon 175) show changes of 
p53 folding, abolishing completely the binding to the DNA and changing the capability to 
interact with other proteins (75). The mechanisms at the root of p53 GOF phenotype have not 
been fully elucidated. Mutant p53 may drive GOF phenotypes by acquiring new functions that 
result in uncontrolled proliferation, survival and motility (73). It has been showed that p53 
mutants use several way in order to regulate the transcription of their targets by which can 
exert GOF function (Fig.9).  
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Fig.9: Mechanism of action of Mutant p53. Mutant p53 can be recruited on the promoter region of its gene 
targets by: a) interaction with other transcription factors; b) direct biding to DNA; c) interaction protein-protein 
(Donzelli S, Biagioni F et al; Curr Genomics,2008 May; 9 (3):200-7). 
 
Although they cannot bind canonical p53 consensus elements by direct binding, they can be 
recruited to regulative elements on the chromatin through interaction with other protens and 
transcription factors, such as NF-Y(76), ETS1(77), ETS2 (78), p73 and p63 (79, 80), Mre11, 
PLK2  and contribute to the regulation of their target genes (Fig.9). Moreover, it has been 
shown that mutant p53 can be recruited onto a subset of p63-responsive elements in the 
moters of genes upregulated and downregulated by p63 (81).  
 
Fig.9. Activation of transcription by mutant p53. Mutant p53 acquires transcriptional activities by interacting 
with transcription factors such as NF-Y, Ets-1/2, p63/p73, E2Fs, PLK2, Mre11 and Tim50, which induce the 
recruitment of mutant p53 to regulatory regions on the chromatin. 
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It has been described that the transcription factor NF-Y binds to the CCAAT consensus motif 
present in the promoters of several cell cycle regulating genes, such as E2Fs and cyclines, and 
contributes to the modulation of their expression, through selective recruitment of acetylases 
and/or deacetylases (76). Upon DNA damage, the complex mutant p53/NF-Y drives the 
transcription of the cell cycle progressing genes cyclin A, B1 and B2, cdk1 and cdc25C, 
resulting in an increased DNA replication which constitutes an important aspect of mutant 
p53 GOF activities (76). Both WT p53 and mutant p53 are able to physically interact with 
the Polo-Like Kinase 2 (PLK2) protein, that plays a critical role in the arrest of cell in 
response to DNA damage (75). Another interactor of mutant p53 is Mre11. This protein forms 
with Rad50 and NBS1 a complex (MRN) involved in sensing DNA damage and recruiting the 
ATM kinase to the sites of DNA damage. When mutant p53 binds to Mre11 prevents the 
recruitment of the MRN complex to the sites of DNA double strand brakes (DSBs) leading to 
an impaired ATM response, that generate higher genetic instability (82). Since the interaction 
with novel partners confers mutant p53 new functions, many efforts are being made to 
identify additional interaction partners for mutant p53, especially in different contexts and in 
response to different stimuli (83). Moreover, mutant p53 can exerts its GOF function through 
the direct binding to the DNA. There is some evidence to show that mutant p53 binds to DNA 
on the chromosome, particularly in G/C rich areas around transcription start sites of some 
genes that are characterized by active chromatin marks (84). Furthermore, mutant p53 interact 
in a stereo-specific way with non-B DNA structures (85, 86). It has been shown that mutant 
p53 not only loses its suppressor functions but also can gain new oncogenic function 
contributing to the arising and maintenance of cancer (87). These mutants belong to the 
second category named gain of function (GOF) mutations. In dominant negative mutations, 
mutant p53 can form hetero-oligomers with wild type (WT) p53 abrogating WT p53 tumor 
suppressor functions. Usually, one allele of the p53 gene is mutated (point mutated), 
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generating a dominant negative mutant protein that may inactivate the co-expressed WT p53 
resulting in weaker tumor suppression (p53:its mutations and their impact on transcription). 
This could be at the root of the increased cancer susceptibility of patients with Li-Fraumeni 
syndrome (88). Also GOF mutant p53 perform a dominant oncogenic role but it does not 
depend on complex formation with WT p53. Several laboratories have performed chromatin 
immunoprecipitation (ChIP) experiments to identify specific mutant p53 consensus sequences 
but, so far, no one has been identified (89). An important approach to detect the specific set of 
gene targets for each mutant p53 is the use of “ChIP-on-chip” and Chip-seq analyses and it 
could contribute to the identification of transcriptional activity of p53 mutants (90, 91, 92). In 
addition, a series of microarray analyses performed in different cell lines have shown that 
mutant p53 can modulate the expression of several genes (93). However, the scenario appears 
very complex because of the great heterogeneity of p53 mutations. In particular,  each mutant 
of p53 can regulate the expression of a pattern of genes only partially overlapping with the 
ones of other p53 mutants. In fact, different mutations in p53 cause interaction with different 
sets of partners (75). The most known gain of function activity of mutant p53 is the induction 
of cell proliferation. Several studies have been conducted and the genes c-fos, c-myc, PCNA, 
cyclin A, B1, B2, cdk1 and cdc25c have been identified as specific targets of mutant p53, 
which can promote cell proliferation (75). Mutant p53 can exert its pro-invasive and pro-
angiogenic activities mainly through the activation of its target genes ID4 and the chemokines 
CXCL1, CXCL5, CXCL8 and CXCL12 as well as MMP-13 and EGFR (75). Recently, p53 
mutants have been involved in microRNA regulation. Donzelli et al. have shown that mutant 
p53R175H can induce the expression of miR-128-2 inducing chemoresistance in many 
cancers (94). It has been described that p53 mutants R175H, R273H and C135Y can 
downregulate the expression of miR-130b, which leads to upregulation of the transcriptional 
repressor ZEB1. This activates the ZEB1 signaling pathway which induces Epithelial-
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Mesenchymal-Transition (EMT) (95). miR-155, which is upregulated in breast cancers, is 
activated by mutant p53 and promotes EMT through inhibition of genes such as ZNF652 (75). 
Moreover, mutant p53, recruited by ZEB1, binds the promoter region of miR-223, leading to 
mutant p53-mediated chemoresistance (96). The biological response to GOF p53 mutants was 
observed first in mouse tumor systems in which expression of a mutant p53 protein resulted in 
tumor formation (73). Using cell and animal model systems, expression of mutant p53 has 
been shown to result in oncogenic and proliferative processes (97) (increased tumorigenicity; 
increased growth in soft agar; decreased sensitivity to chemotherapeutic; increased resistance 
to γ-irradiation; accelerated chemical carcinogenesis; increased homologous recombination 
induced by ionizing radiation; destruction of the spindle check point activated topoisomerase I 
activity; increased DNA synthesis and increased growth rate; induction of gene amplification; 
cooperation with the TGF-β pathway; induction of cellular motility; invasive capability and 
metastasis; somatic cell reprogramming; increased tumor angiogenesis; promotion of chronic 
inflammation and associated cancer (75). Several mouse models have been generated to test if 
the expression of p53 mutants in mice will induce GOF activity. For example, Liu et al. using 
a knock-in mouse line, demonstrated an increased metastatic potential in mice inheriting p53-
R172H (homologous to human p53-R175H) (98, 99). Moreover, Wang et al. (100) showed 
some evidence of gain of function associated with genomic instability using a murine p53-
R172H mutant transgenic model system. Murphy et al. (101) used the same mutant in a 
mammary epithelial murine cell model and find similar results. However, the most 
unequivocal demonstration of gain of function activity in mouse systems was shown when 
mutant p53 was stabilized by knockout of MDM2 or p16 (102). Being p53 mutated in more 
than 50 % of human cancers, restoration of p53 WT functions in cancers bearing mutant p53 
represents a strategy for cancer therapy. In the era of translational cancer research, when the 
aim is to design specific therapy for each patient, the establishment of the characteristic 
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expression of gene such as p53 mutants is becoming of main importance. For this reason, 
many efforts have been made to establish differential signatures between normal and 
cancerous tissues and among the patients, in relation to various parameters altered in cancer, 
among which p53 (75). 
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Human osteosarcoma cancer stem cells 3AB-OS 
It is well known that solid tumors are organized hierarchically and that a distinct 
subpopulation of cells, named cancer stem cells (CSCs), is at the root of their growth and 
chemoresistance (103).  It has been also demonstrated  that CSCs are in the majority of 
tumors and in OS they seem to contribute to the initiation and development of the cancer 
(104). According to this, the research aimed at identifying the CSCs within the cancer cell 
population in order to identify specific therapies for tumor eradication.  Recently, a human OS 
CSC line (3AB-OS) has been produced and isolated, for the first time, from the human 
osteosarcoma MG63 cell line by chemical treatment (105). In this regard, it has been shown 
that treating for a short time (24-72 h) MG63 cells with 3-aminobenzamide (3AB), a 
competitive inhibitor of poly (ADP-ribose) polymerase, their growth rate resulted markedly 
reduced and cells showed morphological features of osteocyte differentiation (106). Osteocyte 
differentiation was accompanied by a reprogramming of gene expression, with down-
regulation of genes required for proliferation and up-regulation of those involved in 
osteoblastic differentiation. Studying the effects of the 3AB treatment for longer times (about 
100 days) it was observed an increasing number of dead cells with a simultaneous and 
progressive enrichment of a new cell population, named 3AB-OS (107; Fig.10). 
 
Fig.10. Production of 3AB-OS cells from human osteosarcoma MG-63 cells by prolonged 3AB treatment. 
The figure describes the morphology of MG-63 cells treated either with vehicle (control, A) or with 5mM3AB 
(B–H) analyzed by contrast phase microscopy as described in Materials and Methods and in Results Sections. 
Original magnification 200X. 
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The characterization of 3AB-OS cell population demonstrated that it is heterogeneous and 
stable. Moreover, after serial passages (currently, more than 200) in the absence of 3AB 
treatment this cells maintained their morphological and antigenic features. 3AB-OS cells 
showed  the most important features of CSCs such as unlimited proliferative potential, 
ABCG2-dependent phenotype with high drug efflux capacity, strong expression of stemness 
and anti-apoptotic genes (105). Furthermore, they showed multi-lineage differentiation 
ability, favouring the mesenchymal lineage, with activation of myoblast differentiation and 
the appearance of muscle fibers in the tumor mass (108). Moreover, AB-OS CSCs showed a 
really good ability to growth in ultra-low attachment forming sarcospheres and they were be 
able to penetrate Matrigel with an invasion ability higher than MG63 parental cell of 2.6 fold 
genes (105).  3AB-OS cells showed a really high aggressive potential and when they were 
xenografted in athymic mice, in the presence of matrigel, they induced the formation of a 
great number of blood vessels (109). Overall, for the first time this provided a mouse model 
which recapitulate in vivo the key aspects of human osteosarcoma CSCs. During the multistep 
development of human tumors, the cells acquire a number of biological abilities such as 
unlimited proliferative signalling, evasion of growth suppressors, cell death resistance, 
replicative immortality, angiogenesis induction, invasion and metastasis activation. All these 
features are recognized as cancer hallmarks (110). The acquisition of these hallmarks results 
from genomic instability from which derives the genetic diversity that accelerates their 
acquisition. Recently, several studies suggested that tumor bioenergetics and CSCs might be 
related to each other (111, 112, 113, 114, 115). To characterize the energetic properties of 
3AB-OS CSCs, their bioenergetics features were analyzed comparing them with the parental 
MG63 OS cells. Through these analyses it has been demonstrated that 3AB-OS cells depend 
on glycolytic metabolism more strongly than MG63 cells. Moreover, 3AB-OS cells show 
lower levels of mitochondrial respiration, are more sensitivity to glucose depletion or 
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glycolytic inhibitors and show a reduced sensitivity to inhibitors of oxidative phosphorylation. 
Furthermore, 3AB-OS have more fragmented mitochondria, respect to MG63 cells, which 
rapidly networked in the presence of glucose-rich medium. When they growth in low glucose 
conditions they completely lose these structures. Overall, the above findings suggested that 
the energy metabolism of 3AB-OS CSC strongly resemble that of normal stem cells and 
cancer cells, which are characterized by a glycolytic anaerobic metabolism (116). Cancer cells 
are characterized by multiple genetic/epigenetic changes that are responsible for chromosomal 
instability and tumor progression (117). Most of these changes consist in aberrations with loss 
or gain of gene function of many tumor suppressors. 3AB-OS cells have a large chromosomal 
complexity and molecular abnormalities characteristic of the most aggressive human cancers. 
Indeed, they have a hyper triploid karyotype and chromosome number ranging from 71 to 82, 
whereas MG63 cells have a hypotriploid karyotype and chromosome number ranging from 61 
to 66. Moreover, 3AB-OS cells show monosomies, trisomies and nullisomies; they have 32 
unidentifiable marker chromosomes and, compared with MG63, they have 49 copy number 
variations (gains/losses) affecting almost all the chromosomes (118). Intriguingly, the 
abnormalities evidenced in 3AB-OS cells are very similar to those described in a large 
number of pediatric and adult osteosarcomas, where karyotypes ranging from haploid to near 
hexaploid have been shown (119, 120, 121). Moreover, 3AB-OS cells showed losses/gains in 
agreement with those seen in osteosarcoma patients (119, 120, 121). By microarray analysis, 
where 3AB-OS cells have been compared with MG63 cells, the gene expression profile of 
3AB-OS cells was studied. Employing KEGG and BioCarta analysis, 196 genes which 
resulted up-/down-regulated and which appeared to be involved in regulatory pathways of 
tumorigenesis and stemness (ECM-receptor interaction and cell communication; cell adhesion 
molecules; ABC transporters in general; Notch and Hedgehog signalling; MAPK signalling; 
cell cycle regulators; apoptosis) have been selected. Most of these genes have been reported in 
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osteosarcoma patients (122). Moreover, by human MicroRNA array analysis it was possible 
to identify 189 differentially expressed miRNAs and the analysis of mRNA/miRNA 
expression profiles appeared to be very similar to those reported in human OS patients (123, 
124). Furthermore, to define a surface protein signature specific for 3AB-OS CSCs and MG63 
cells, a cytometric analysis has been performed using an antibody-array consist in 245 
membrane proteins. It has been also selected MAPK/ERK1/2 as a potential protein kinase-
pathway correlated with pathways that characterize tumorigenesis and stemness of 3AB-OS 
cells (125) More than half of all cancers exhibit mutation at p53 locus on the short arm of 
chromosome I7 at I7p13 (126). Wild-type human p53 transcriptionally targets a large number 
of genes which mediates cell cycle arrest, DNA repair, senescence, apoptosis, and various 
metabolic processes. The loss of p53 function has been usually associated with an impairment 
of these functions (127). TP53 missense mutations represent the majority of cancer-associated 
mutations which lead to the expression of a full-length altered p53 protein which, in contrast 
to wild-type p53, has a prolonged half-life. These missense mutations even determine 
oncogenic or gain-of-function activity (128, 129). Recently (130), TP53 gene status/role in 
3AB-OS CSC line has been studied and it has been shown that it is involved in promoting 
proliferation, invasiveness, resistance to apoptosis and stemness. In particular, it has been 
shown that, in comparison with parental MG63 cells (where TP53 gene is hyper methylated, 
rearranged and in single copy), 3AB-OS cells have TP53 gene unmethylated, rearranged and 
in multiple copies. Moreover, mutp53 (p53-R248W/P72R) is post-translationally stabilized 
and with nuclear localization. Interestingly, p53-R248W/P72R-knockdown by short-
interfering RNA, reduced the growth and replication rate of 3AB-OS cells, markedly 
increasing cell cycle inhibitor levels and sensitizing 3AB-OS cells to TRAIL-induced 
apoptosis. Furthermore, the knockdown strongly decreased the levels of stemness and 
invasiveness genes. Recently, in 3AB-OS CSCs it has been described a predictive network for 
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let-7/98 and miR-29a, b, c, (two deeply down regulated miRNA family) and MSTN, CCND2, 
Lin28B, MEST, HMGA2, GHR (their anti-correlated and highly up regulated mRNAs). 
These miRNAs/mRNAs may represent new biomarkers for OS and could permit the 
identification of new potential therapeutic targets (118). These miRNAs will be overexpressed 
in 3AB-OS cells in order to study their effects on 3AB-OS stemness and behaviour. 
Moreover, it has been hypothesized that p53 mutation could be the “driver mutation” at the 
root of the dedifferentiation of MG63 cells into 3AB-OS CSCs (130). This PhD research 
project has been developed in order to demonstrated this hypothesis.  
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PROJECT AIM 
 
During the last ten years the existence of cancer stem cells has been discussed. Numerous 
studies suggest that these cells have an important role in the development and maintenance of 
the tumor (42) The actual theory suggests that tumors consist of subsets of cells with 
functional heterogeneity among which  there is a subset of cells with stem features (131) 
Therefore, the tumor can be imagined as a real organ where the various cells have very 
specific tasks and roles in the organization of the life of the tumor. The existence of cancer 
stem cells has been well supported by numerous studies and has been shown that they are 
resistant to cancer therapies causing the tumor recurrence (132).The understanding of the 
mechanisms at the roots of the growth, survival and expansion of cancer stem cells is crucial 
to detect specific treatments for tumor eradication. This PhD project has been developed at the 
University of Palermo, in the laboratories of the Section of Biochemistry, Polyclinic, of the 
DPT STEBICEF, coordinated by Prof. Renza Vento and in part in the laboratories of the 
Biothec Research and Innovation Centre (BRIC) at the University of Copenhagen directed by 
Professor Anders Lund. Professor Vento’s research groups has produced a great number of 
paper on the study of the activation of apoptosis pathways after the treatments with several 
drugs in order to find specific targets for anti-tumor therapies. During the last years one of the 
lines of research developed in these laboratories concerned the study of the molecular 
mechanisms that might be at the origin of the cancer stem cell. Professor Lund’s group has a 
great expertise in biomolecular biological studies focused on the analyses of genetic and 
epigenetic mechanisms in both tumor and normal cells line. My PhD research project is part 
of a more complex project on the 3AB-OS cancer stem cell line, coordinated by Professor 
Vento. Her research group, employing the osteosarcoma MG63 cells, has produced by 
chemical treatment a novel cell line which has been termed “3AB-OS” and which has been 
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patented (F12008A000238, Florence, 11/12/2008, Renza Vento, Riccardo Di Fiore). 3AB-OS 
cells show various features of cancer stem cells, including unlimited proliferative potential 
and expression of genes required for maintaining stem cell state (CD133, Oct3/4, hTERT, 
nucleostemin, Nanog) and for inhibiting apoptosis (HIF-1alpha, FLIP-L, Bcl-2, XIAP, IAPs 
and survivin). Moreover, 3AB-OS cells efficiently transdifferentiate, in vitro, into cells of all 
three primary germ layers (ectoderm, endoderm and mesoderm) and when injected into 
athimic mice, they recapitulate in vivo various features of human osteosarcoma.  Thus, 3AB-
OS cells can represent a useful model system to test in vivo novel antitumor approaches 
against human osteosarcoma. The research group has even genetically e molecularly 
characterized 3AB-OS cells. Overall, it has been suggested that 3AB-OS cells should 
represent an invaluable tool for studying the molecular mechanisms underlying osteosarcoma 
origin and stemness. Moreover, it has been shown that the energy metabolism of 3AB-OS 
CSCs strongly resemble that of normal stem cells and cancer cells, which are characterized by 
a glycolytic anaerobic metabolism (116). 3AB-OS cells have a large chromosomal complexity 
and molecular abnormalities characteristic of the most aggressive human cancers (118).  
 My participation in the research on 3AB-OS CSCs started when it has been showed that 
these cells contain a mutant p53 protein which could be responsible for their stemness 
properties. In particular, it has been shown that, compared with parental MG63 cells, where 
TP53 is not expressed and in single copy, 3AB-OS cells strongly express a mutp53 protein 
whose TP53 gene is rearranged and in multiple copies characterized by P72R polymorphism 
and hot spot mutation R248W. In addition, mp53 is stabilized by post-translational 
modifications (phosphorylation at Ser15 and acetylation at Lys 320, Lys 373-382). Depletion 
of mp53 by small-interfering-RNA induced a decrease in cell proliferation and migration 
accompanied by apoptosis resistance and by the coherent expression of genes controlling cell 
cycle, apoptosis and invasiveness. Moreover, mp53 knockdown affected the expression of 
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pluripotent markers as Oct3/4, Nanog, Sox2 and Nucleostemin, suggesting that it might affect 
pluripotency potential of 3AB-OS cells. Overall, the results suggested an oncogenic role of 
mp53 and its contribution to stemness and chemoresistance characteristics of 3AB-OS. The 
hypothesis was that p53-R248W/P72R could be at the root of the dedifferentiation of MG63 
into 3AB-OS CSCs (130).  
 My PhD research project aimed to elucidate the molecular mechanisms underlying gain of 
function of this mutant p53 and to evaluate its potential contribution in maintenance of 
stemness properties of 3AB-OS cells. 
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Study of gain of function of p53-R248W/P72R in 3AB-OS cells 
In order to evaluate whether, in 3AB-OS cells, p53-R248W/P72R has acquired GOF activities 
such as enhanced cell proliferation, invasiveness and resistance to apoptosis, we have 
determined the knockdown of the protein by small interfering RNA (siRNA) , transfecting 
3AB-OS cells with either a p53-siRNA and a scramble siRNA (Scr-siRNA). First, we 
checked the efficiency of p53 silencing effects evaluating the changes on endogenous p53 
levels. At 24–72 h after transfection, the content of the protein was assessed by western blot 
(Fig. 1A) and immunofluorescence (Fig. 1B) analyses. Both the analyses showed that p53-
R248W/P72R levels potently lowered by p53-siRNA transfection. The lowering was already 
well evident at 24h after transfection where more than 35% decrease was observed. Then, it 
was maximal at 48h when more than 70% decrease in the level of the protein was evidenced. 
Thereafter, p53-R248W/P72R levels markedly went up, so that at 72 h after transfection, only 
a 22% decrease was observed. This suggested that, at that time, the transient silencing was in 
rapid recovery. Overall, the results suggested that the optimal silencing efficiency was 
reached at 48h after transfection. The knockdown of the protein was specific as no protein 
decrease was observed in cells transfected with Scr-siRNA. 
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Fig. 1. Evaluation of knockdown efficiency of p53-R248W/P72R. 3AB-OS cells were transfected with 
scrambled siRNA (Scr-siRNA) or p53-siRNA and analyzed at 24–72 h after transfection. (A) Western blot 
analysis of p53-R248W/P72R and densitometric analysis of protein bands. Data (relative density normalized to 
actin) represent the mean with standard deviation (n = 4); *P b 0.05 and **P b 0.01 as compared to Scr-siRNA-
transfected cells. (B) Immunofluorescence analysis by double staining cells with both Hoechst33342 dye (blue), 
to localize the nuclei, and anti-p53 antibody and Cy3-conjugated secondary antibody (red), to localize p53. The 
scale bar represents 25 μm. Images are representative of four independent experiments 
 
p53-R248W/P72R-knockdown affects 3AB-OS cell proliferation rate 
To evaluate whether p53-R248W/P72R-knockdown modified the growth of 3AB-OS cells, 
untransfected cells and cells transfected with Scr-siRNA or with p53-siRNA were 
microscopically observed and analysed (0–72 h) for cell number, percentage of cells in the  
S-phase of cell cycle (EdU incorporation) and percentage of viability. As Fig. 2A shows, in 
3AB-OS silenced for p53-R248W/P72R, in comparison to untransfected or Scr-siRNA-
transfected cells, cell number lowered. Fig. 2B also shows that p53-R248W/P72R silencing 
reduced the growth rate and the replication rate of 3ABOS cells, whereas the cell viability had 
A                                                              B 
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not been affected. The speed of cell growth and replication reflected the trend of p53-
R248W/P72Rknockdown. 
 
 
Fig.2. Effect of p53-R248W/P72R-knockdown on growth advantage of 3AB-OS cells. (A) Inverted phase 
contrast microscopy at 0–72 h after transfection. The scale bar represents 100 μm.Images are representative of 
four independent experiments. (B) Analysis of total cell number (a), percentage of cells in the S-phase of cell 
cycle (b) by EdU incorporation and percentage of cell viability (c). The data represent the mean with standard 
deviation (n = 4); *P < 0.05 and **P < 0.01 as compared to Scr-siRNA-transfected cells 
 
Next, we examined the expression of several cell cycle-related proteins and genes at 48 h post 
transfection. In Fig. 3, western blot and real-time PCR analyses showed that the  
p53-R248W/P72R-knockdown markedly increased the levels of pRb, p130, p107, E2F1, 
E2F4, GADD45, p21 and p27,whereas it potently decreased CDK4 levels. No alteration in the 
expression of cyclins and other CDKs was observed. 
p53-siRNA 
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Fig.3. Analyses of cell-cycle regulators at 48 h after silencing. (A) Western blot analysis and quantification of 
protein bands by densitometric analysis; data (relative density normalized to actin) represent the mean with 
standard deviation (n = 4); *P < 0.05 as compared to Scr-siRNA-transfected cells. (B). Real-time PCR. Data 
(fold change) represent the mean with standard deviation (n = 4); #P < 0.005 as compared to Scr-siRNA-
transfected cells. 
 
p53-R248W/P72R-knockdown increases 3AB-OS sensitivity to apoptotic events. 
Previous analyses demonstrated that 3AB-OS cells express low levels of the death receptors 
FAS and DR4 (118) and show strong resistance to TRAIL (TNF-related apoptosis inducing 
ligand). Here, we evaluated whether the p53-R248W/P72R-knockdown modifies the 
expression levels of DR4 (TRAIL-R1), KILLER/DR5 (TRAIL-R2) and FAS/CD95.  In Fig. 
4, western blot analyses show that at 48 h post-transfection p53-R248W/P72R knockdown 
A 
 
 
 
 
 
 
 
 
 
 
B 
35 
 
increased protein expression levels of DR4 and DR5, whereas no significant changes in FAS 
levels were observed. In order to evaluate TRAIL sensitivity, untransfected cells and cells 
transfected for 24h with Scr-siRNA or p53-siRNA were treated with TRAIL (40 ng/ml) for 
36h.  
 
Fig. 4. Effect of p53-R248W/P72R-knockdown on DR4, DR5 and FAS receptors. Western blot analysis of 
DR4, DR5 and FAS receptors at 48 h after transfection and quantification of protein bands by densitometric 
analysis. Data (relative density normalized to actin) represent the mean with standard deviation (n = 4); *P < 
0.005 as compared to ScrsiRNA-transfected cells. 
 
In Fig. 5A, phase contrast microscopy shows that TRAIL markedly reduced cell number also 
inducing apoptosis in p53-silenced cells, as suggested by the presence of round-shaped cells 
floating in the medium, membrane blebbing and apoptotic body formation. Apoptosis was 
analyzed by staining nucleic acid with Hoechst 33342 to check chromatin condensation and 
nuclear fragmentation. As shown Fig. 5A, in p53-siRNA transfected cells, TRAIL induced 
typical apoptotic nuclei, exhibiting highly fluorescent condensed and fragmented chromatin. 
Apoptosis was also studied by flow cytometry of either DNA content (5B) or annexin V 
labelling (5C). The treatment with TRAIL resulted in 29% of cells accumulated in sub-G0–
G1 phase with a 20% of early apoptotic cells (annexin V+/PI−) in p53-siRNA-transfected 
cells. The effects of TRAIL in both untransfected and Scr-siRNA transfected cells were much 
less conspicuous than in p53-siRNA-transfected cells. Collectively, these results demonstrate 
that p53-R248W/P72R knockdown sensitizes 3AB-OS cells to TRAIL induced apoptosis.  
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Fig.5. Effect of p53-R248W/P72R-knockdown on TRAIL-induced apoptosis. (A) Analysis of TRAIL-
induced apoptosis by inverted phase contrast microscopy (upper panels) and fluorescence microscopy (Hoechst 
33342 staining, bottom panels). The scale bar represents 25 μm. Images are representative of four independent 
experiments. (B) Percentages of cells in sub-G0–G1 phase evaluated by flow cytometric analysis of propidium 
iodide DNA staining, and percentages of early apoptotic cells (C) measured by flow cytometric analysis of 
annexin V labelling after TRAIL treatment (1, untransfected cells; 2, cells transfected with  
Scr-siRNA; 3, cells transfected with p53-siRNA). The data represent the mean with standard deviation (n = 4). 
*P < 0.05 and **P < 0.01 as compared to untreated cells. 
 
It was also investigated, by cytofluorimetric analysis, if p53-R248W/P72R can attenuate 
mitochondrial apoptosis signalling pathways. DiOC6 staining revealed that the p53-
R248W/P72R knockdown induced a significant decrease in fluorochrome uptake, indicating a 
loss of mitochondrial membrane potential Δψm (Fig. 6A). To evaluate the mechanism 
involved, the expression levels of both anti-apoptotic (Bcl-2 and Bcl-XL) and pro-apoptotic 
(Bax and Puma) factors in p53-siRNA-transfected and Scr-siRNA transfected 3AB-OS cells 
were also investigated. In Figs. 6B and 6C, real-time PCR and western blot analyses showed 
that the p53-R248W/P72R knockdown significantly decreased Bcl-2 and Bcl-XL levels while 
37 
 
it increased Bax and Puma levels. These results well agreed with those obtained by 
cytofluorimetric analysis. 
 
Fig.6. Effect of p53-R248W/P72R-knockdown on mitochondrial membrane potential and Bcl-2 
familymembers (A) Citofluorimetric analysis by DiOC6 staining of mitochondrial membrane potential (Δψm). 
The decrease of fluorescence intensity indicates loss of Δψm. (B) Real-time PCR analysis of Bcl-2 family 
mRNAs at 48 h after transfection. Data represent the mean with standard deviation (n = 4); #P b 0.005 as 
compared to Scr-siRNA-transfected cells. (C) Western blot analysis of Bcl-2 family proteins at 48 h after 
transfection and quantification of protein bands by densitometric analysis. Data (relative density normalized to 
actin) represent the mean with standard deviation (n = 4); *P b 0.05 as compared to Scr-siRNA-transfected cells. 
 
p53-R248W/P72R promotes cell invasiveness 
 
To evaluate whether p53-R248W/P72R-knockdown influences 3ABOS cells invasiveness, 
Matrigel invasion trans-well assays were performed. As shown in figure 8, p53-siRNA 
transfection determined a potent decrease (−80%) of the invasive ability of 3AB-OS cells, 
whereas no statistically significant difference was observed in untransfected and Scr-siRNA 
transfected cells.  
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Fig.8. Effect of p53-R248W/P72R-knockdown on invasive properties of 3AB-OS cells. In vitro invasive 
capacity of untransfected cells and cells transfected with Scr-siRNA or p53-siRNA through the Matrigel-
transwell membranes after 48 h of incubation. Fluorescence microscope imagines (left panel); data graphed 
(right panel) with the mean of the relative invasion ability of cells, normalized respect to the untransfected cells 
(standard deviation n = 4; *P < 0.05). 
 
It was also examined the expression of a number of invasiveness related genes and proteins at 
48 h post-transfection. In Figs. 9A and 9B, real-time PCR and western blot analyses showed 
that after the knockdown of p53-R248W/P72R the levels of matrix metalloproteinases 2 and 9 
(MMP2 and MMP9), integrin alfa5 (ITGα5) and integrin alfaV (ITGαV) decreased, while the 
levels of the cell adhesion protein E-Cadherin increased. No alterations in the expression of 
proteins involved in mesenchymal phenotype (N-cadherin, β-catenin and vimentin) were 
observed.  
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Fig.9. Effect of p53-R248W/P72R-knockdown on invasive properties of 3AB-OS cells. (A) Western blot 
analysis of both cell invasion and epithelial-mesenchymal-transition-related proteins at 48 h after transfection; 
quantification of protein bands by densitometric analysis. Data (relative density normalized to actin) represent 
the mean with standard deviation (n = 4); *P b 0.05 as compared to Scr-siRNA-transfected cells. (B) Real-time 
PCR analysis of both cell invasion and epithelial-mesenchymal-transition-related genes at 48 h after transfection. 
Data are the mean with standard deviation (n = 4); #P b 0.005 as compared to Scr-siRNA-transfected cells.  
 
p53-R248W/P72R-knockdown affects the expression of stem-cell markers 
Previously, it has been shown that 3AB-OS cells express a large number of genes required for 
maintaining stemness (105) and that they morphologically and functionally transdifferentiate 
in vitro into cells of all three primary germ layers (ectoderm, endoderm and mesoderm) (108). 
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Moreover, stemness markers were profoundly downregulated in differentiated cells. Here, 
fig.10 shows that undifferentiated 3AB-OS cells strongly expressed p53-R248W/P72R while 
it profoundly lowered in derived cell lineages.  
 
Fig. 10. Effect of p53-R248W/P72R-knockdown on various stem-cell markers in 3AB-OS cells. Western 
blot analysis of p53-R248W/P72R in undifferentiated (U) and differentiated 3AB-OS cells and quantification of 
protein bands by densitometric analysis. Data (relative density normalized to actin) represent the mean with 
standard deviation (n = 4);**P b 0.01 as compared to undifferentiated cells. Abbreviations: OD, osteogenic 
differentiation; AD, adipogenic differentiation; HD, hepatogenic differentiation; ND, neurogenic differentiation. 
 
It was also investigated whether the knockdown of p53-R248W/P72R affected the expression 
of the most important stemness markers, such as Oct3/4, Nanog, Sox2, nucleostemin (ns) and 
CD133 that exhibited very high levels in untransfected 3ABOS cells. In Figs. 11A and 11B, 
western blot and real-time PCR analyses showed that in p53-R248W/P72R knockdown cells 
the levels of all the analyzed pluripotency markers potently decreased. 
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Fig. 11. Effect of p53-R248W/P72R-knockdown on various stem-cell markers in 3AB-OS cells. (A) Western 
blot analysis of stemness proteins at 48 h after transfection and quantification of protein bands by densitometric 
analysis. The data (relative density normalized to actin) represent the mean with standard deviation (n = 4);*P < 
0.05 and **P < 0.01 as compared to Scr-siRNA-transfected cells. (B) Real-time PCR analysis of stemness genes 
at 48 h after transfection. Data represent the mean with standard deviation (n = 4); *P < 0.05 and #P < 0.005 as 
compared to Scr-siRNA-transfected cells. 
 
Transient ectopic expression of p53-R248W/P72R in osteosarcoma MG63 cells. 
The above-described findings suggested that the GOF property of p53-R248W/P72R could be 
at the root of 3AB-OS stemness. To evaluate this hypothesis, the effects of transient ectopic 
expression of P53-R248W/P72R were analyzed. MG63 cells were transfected with a 
pcDNA3.1 empty vector VECTOR) and with a pcDNA3.1 vector containing p53-
R248W/P72R (R248W/P72R). First, it was evaluated p53-R248W/P72R protein expression 
and localization in both cellular lines by western blot, flowcytometry and 
immunofluorescence analyses (130). Figure. 12A shows that, as expected, p53 protein was not 
detectable in vector cells, while it was expressed in R248W/P72R cells. This was confirmed 
by a strong positivity for p53 (>75%) in R248W/P72R cells analyzed by cytometry (Fig. 
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12B). Moreover, p53 protein in R248W/P72R cells has a nuclear localization (Fig. 12C) like 
in 3AB-OS cells.  
 
 
Fig.12. Transient ectopic expression of p53-R248W/P72R in osteosarcomaMG63 cells. (A) Western blot 
analysis of p53 in MG63 cells transfected with either pcDNA3.1-p53-R248W/P72R (R248W/P72R) or empty 
pcDNA3.1 vector (VECTOR). The images are representative of four independent experiments. (B) Cytometric 
analysis for p53 in R248W/P72R cells. The open histogram indicates isotype control, filled histogram, indicates 
the expression of p53. The images are representative of four independent experiments. (C) Immunofluorescence 
analysis of p53 in R248W/P72R cells, by double staining cells with both Hoechst 33342 dye (blue, left panel) to 
localize the nucleus and anti-p53 antibody and Cy2-conjugated secondary antibody (green, middle panel) to 
localize p53. In the right panel the merge of the two dyes is shown. The scale bar represents 25 μm. Images are 
representative of four independent experiments. 
 
Thereafter, it was evaluated whether p53-R248W/P72R expression in MG63 cells promoted 
cancer stem-like features, as high proliferation rate, spheres formation, clonogenic growth, 
high migration and invasive ability. First, I compared R248W/P72R and VECTOR cells 
growth. As shown in Fig. 13A, R248W/P72R cells possess a higher proliferative output then 
VECTOR cells, exhibiting a doubling time of approximately 25 h, whereas vector cells show 
a doubling time of 33 h. This result was confirmed by cell cycle analyses performed by 
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cytometry and showing that  R248W/P72R cells were confined mostly in the S-G2\M phase, 
while VECTOR cells were predominantly in G0\G1 (Fig. 13B).  
 
 
Fig.13. Transient ectopic expression of p53-R248W/P72R in osteosarcomaMG63 cells and its effect on cell 
proliferation. (A) Growth curves of VECTOR and R248W/P72R cells. The data represent the mean with 
standard deviation (n = 4); *P < 0.05 and **P < 0.01 as compared to vector cells. (B) Cell cycle distributions in 
VECTOR and R248W/P72R cells determined using flow cytometry. Results are indicated as relative percentage 
of total cell cycle (*P < 0.05, as compared to VECTOR cells). 
 
It has been reported that cancer stem-like cells are able to form spheroid-like bodies under 
serum-free medium with bFGF and EGF (132) For this reason, sarcosphere forming ability of 
R248W/P72R cells compared to VECTOR cells was tested. Fig. 14 (A and B) shows that both 
vector and R248W/P72R cells were able to form sarcospheres. In particular, 5 days post 
seeding, vector cells formed sarcospheres with a mean diameter of 60.2 ± 5.7 μm and a 
frequency of approximately 1/54 (9.3 ± 1.5 spheres/500 cells), while R248W/P72R cells 
formed larger sarcospheres (mean diameter of 68.7 ± 7.6 μm) with a frequency of 
approximately 1/42 (12 ± 2.0 spheres/500 cells). After 10 days, R248W/P72R sarcospheres 
increased in size and number, showing a mean diameter of 110 ± 23 μm with 576 
cells/sphere. Even VECTOR sarcospheres increased in size and number but less respect to the 
R248W/P72R sarcospheres (mean diameter of 74.9 ± 18.2 μm, containing about 214 
cells/sphere). Thereafter, secondary and tertiary sarcosphere-forming ability was analyzed and 
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it was observed that (Fig. 14C) they maintained the same trend of the primary spheres. These 
data demonstrated that R248W/P72R cells acquired a higher in vitro self-renewing potential.  
 
Fig.14.Transient ectopic expression of p53-R248W/P72R in osteosarcomaMG63 cells and its effect on 
sarcosphere-forming ability. (A) Phase contrast images of primary sarcospheres formed from VECTOR and 
R248W/P72R cells after 5 and 10 days post seeding. The scale bar represents 50 μm. Graphs summarizing size 
and number of sarcospheres from 500 cells (days 5 and 10) and number of cells/sphere on day 10. (B) Graph 
summarizing numbers of primary, secondary (generated from dissociated primary spheres) and tertiary 
(generated from dissociated secondary spheres) sarcospheres on day 10 from 500 cells. The data represent the 
mean with standard deviation (n = 4); *P < 0.05, **P < 0.01 and #P < 0.005 as compared to VECTOR cells. 
 
As colony-forming ability is correlated with cell self-renewal (133), this ability was evaluated 
in MG63 cells after transient ectopic expression of the mutant p53 protein. As shown in Fig. 
15 (A and B), R248W/P72R cells formed more and larger colonies than VECTOR cells.  
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Fig.15. Transient ectopic expression of p53-R248W/P72R in osteosarcomaMG63 cells and its effect on 
colony-forming ability. Clonogenic growth of VECTOR and R248W/P72R cells after 10 days post seeding. 
A)Phase contrast images (top left panel; the scale bar represents 200 μm) and a picture (bottom left panel) of 6-
well plate after staining with methylene blue are shown. B) Graphs summarizing plate efficiency (colonies/100 
cells). The data represent the mean with standard deviation (n = 4); **P < 0.01 and #P < 0.005 as compared to 
VECTOR cells. 
 
The motility and invasivity of the cells by wound healing and matrigel transwell invasion 
assays, respectively, were also evaluated. Compared with VECTOR cells, R248W/P72R cells 
showed higher migratory (Figs. 16A and B) and invasive (Figs. 17A and B) activities. These 
data suggested that p53-R248W/P72R expression can significantly promote the migratory and 
invasive function of MG63 cells.  
 
  
Fig.16. Effects of transient ectopic expression of p53-R248W/P72R on cell migration in MG63 cells. (A) 
Representative images from the scratch wound healing assay in MG63 cells transfected with either pcDNA3.1-
p53-R248W/P72R (R248W/P72R) or empty pcDNA3.1 vector (Vector). Cells were scratched and wound 
margins were evaluated 0, 8 and 24 h later. The scale bar represents 100 μm. (B) Quantification of the scratch 
wound-healing assay is graphed. The data represent the mean with standard deviation (n = 4); *P < 0.05 as 
compared to VECTOR cells 
A                                                               B 
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Fig.17. Effects of transient ectopic expression of p53-R248W/P72R on cell invasion in MG63 cells. (A) 
Representative images from the trans-well invasion assays in VECTOR and R248W/P72R cells. After 48 h of 
incubation, cells migrated to the underside of the insert were stained with Hoechst 33342. The scale bar 
represents 50 μm. (B) Graph of the relative invasion; the data represent the mean with standard deviation (n = 4; 
*P < 0.05). 
 
In order to determine whether R248W/P72R cells could express the main cancer stem cell 
markers, the expression profile of two representative stem cell surface markers of OS, CD133 
and ABCG2 was analyzed by flow cytometry (105) Fig. 18A shows a very low cell surface 
expression of CD133 and ABCG2 in both VECTOR cells (0.7% and 1.5%, respectively) and 
R248W/P72R cells (0.9% and 4.3%, respectively) and a high intracellular positivity (Fig. 
18B), in both cellular conditions (24.5% of CD133 and 88.3% of ABCG2 in R248W/P72R 
cells; 8.3% of CD133 and 63.1% of ABCG2 in VECTOR cells). These results were 
confirmed by western blot analyses where the up-regulation (1,38 fold for CD133 and 1,25 
fold for ABCG2) in R248W/P72R cells compared to VECTOR cells (Fig. 18B) was observed. 
Furthermore, the expression levels of the proteins that are involved in the regulation and 
maintenance of the stem cell phenotype, such as Nanog, OCT3/4, nucleostemin (NS) and 
Sox2 were analyzed. Western blot analyses (Fig. 18C) showed that these markers were 
significantly higher in R248W/P72R cells, with an increase of 1.56-fold, 1.22-fold and 1.37-
fold for Nanog, OCT3/4 and ns, respectively (Fig. 18D). Significant changes in Sox2 levels 
were not observed. The above data demonstrated that the transient ectopic expression of 
mutant protein p53-R248W/P72R in MG63 cells, promotes cancer stem-like features. 
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Fig.18. Effects of transient ectopic expression of p53-R248W/P72R on stemness markers expression 
inMG63 cells. (A) Cytometric analyses showing cell surface expression of CD133 (left panels) and ABCG2 
(right panels) in VECTOR and R248W/P72R cells. The open histograms indicate isotype control; filled 
histograms indicate the expression of CD133 and ABCG2. (B) Cytometric analyses showing intracellular 
expression of CD133 (left panels) and ABCG2 (right panels) in VECTOR and R248W/P72R cells. The open 
histograms indicate isotype control; filled histograms indicate the expression of CD133 and ABCG2. (C and D) 
Western blot analysis of stemness proteins and relative densitometric analysis. The data (relative density 
normalized to actin) represent the mean with standard deviation (n = 4); *P < 0.05 and **P < 0.01 as compared 
to vector cells. 
 
p53-R248W/P72R stable knockdown reduces cancer stem-like properties in human 
cancer stem cells 3AB-OS.  
In order to confirm that p53-R248W/P72R is involved with the maintenance  of 3AB-OS 
stemness the mutant p53 was silenced using stable RNAi system. Five days post selection the 
efficiency of silencing was evaluated by western blotting analysis, qPCR and 
immunoflurescence, comparing three cellular conditions: 3AB-OS, sh-scramble 3AB-OS 
(Scramble) and sh-p53 3AB-OS (sh-p53). As figure 19 (A, B and C) shows, the efficiency 
was more than 90%.  
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Fig. 19. Evaluation of stable knockdown efficiency of p53-R248W/P72R. 3AB-OS cells were transfected 
with scrambled shRNA (Scramble) or p53 shRNA (shp53) and analyzed at 5 days after infection. (A) Western 
blot analysis of p53-R248W/P72R. (B) Real time PCR analysis of p53-R248W/P72R 5 days post infection. Data 
represent the mean with standard deviation (n = 4); **P < 0.01 as compared to Scramble cells. (C) 
Immunofluorescence analysis by double staining cells with DAPI (blue), to localize the nuclei, and anti-p53 
antibody and Alexa-fluo secondary antibody (green), to localize p53. Images are representative of four 
independent experiments 
 
The cell line selected after p53-knockdown showed different aspects respect to the parental 
3AB-OS and Scramble cells. Indeed, as shown in figure 20, the cells appeared bigger and 
polygonal and similar to each other respect to the control conditions. Moreover, there was a 
higher percentage of multinucleated giants cells respect to the Scramble and not silenced 
cells.  
** 
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Fig.20. Morphologic analysis of stable p53-R248W/P72R knockdown cells. Inverted phase contrast 
microscopy after cells selection. The image shows 3AB-OS cells (left), Scramble (middle) and sh-p53 (right). 
The arrows evidenced the multinucleated giants cells.  
 
Then, we evaluated whether p53-R248W/P72R stable knockdown affected 3AB-OS cancer 
stem-like features, such as proliferation rate, spheres and colonies formation, migration and  
expression levels of main stemness makers. First, we evaluated cell growth in sh-p53 cells 
compared with Scramble cells. MTS assay (fig.21A) showed in sh-p53 cells a decrease of cell 
proliferation confirmed by a decrease of S and G2/M cell cycle phases, accompanied by an 
increase in G1 cell cycle phase cell cycle (fig.21B) and a smaller percentage of EdU 
incorporation (fig.21C). As shown in figure 21D, p53R248W/P72R stable knockdown 
determined the decrease in expression levels of CycB1, CycD1, CDK6 that are important 
positive cell cycle regulators and the increase in p21 and p27, that represent negative 
regulators of cell cycle. These data were confirmed by real time PCR analyses (fig.21E) by 
which it has been observed a decrease in the expression levels of cycD1, cycD2, cycE1, 
cycE2 and an increase of CDKN2C, the inhibitor of CDK4. These results showed that after 
p53-R248W/P72R knockdown reduce the speed of the proliferation rate of 3AB-OS cells. 
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Fig.21. Effects of p53R248W/P72R: Proliferation rate. A) MTS assay performed among 0 and 96 hours after 
seeding; B) cell cycle distribution determined by flow cytometry. The data are indicated as relative percentage of 
total cell cycle (*P < 0.05 compared to the Scramble cells); C) Edu-incorporation assay performed by flow 
cytometry. D) western blotting analysis of important cell cycle regulators; E) Real-time PCR analysis of cell 
cycle regulators. Data represent the mean with standard deviation (n = 4); **P < 0.005 as compared to the 
Scramble cells. 
 
These proliferation data, together with the increase in multinucleated giant cells, suggested 
that p53R248W/P72R stable knockdown could lead the cells to the acquisition of a senescent 
phenotype. In order to verify this hypothesis we performed β−galactosidase and Senescence 
Associated Heterochormatin Foci (SAHF) assays. There are many evidences that show high 
β-galactosidase levels in senescence cells (134). As figure 22A evidences there were more 
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blue cells in sh-p53 cells then in Scramble condition. These results suggest that silencing the 
mutant-p53 promotes the senescent state in 3AB-OS cells. 
 
Fig. 22. Study of senescence state after p53-R248W/P72R stable knockdown. Contrast phase images of 
Scramble (left image) and sh-p53 (right image) after β-galactosidase assay; the blue cells senescent  are 
evidenced by the arrows. 
 
Thereafter, experiments were performed to understand if mutant p53 stable knockdown 
affected apoptosis. Western blotting analysis (Fig. 23A) showed that stable p53-R248W/P72R 
knockdown induced an increase in the levels of Bax and Bad, pro-apoptotic Bcl-2 family 
members, and a decrease in the levels of Bcl-2 the anti-apoptotic factors of the same family. 
The study of Lamin B shows in sh-p53 cells a decrease in its levels, while caspase-3 and 
PARP evidenced no significant differences in protein levels between Scramble and sh-p53 
cells. Cell cycle analysis (fig.23B) shows a small increase in the subG0G1 phase in 3AB-OS-
shp53 compared to the Scramble cells. Overall, these findings suggested that 3AB-OS cells 
with p53R248W/P72R knockdown are prone to the apoptotic event. 
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Fig.23. Effect of p53-R248W/P72R-knockdown on apoptosis. A) western blotting analisys of Bcl-2 family 
member and caspase-3 pathway; B) ) cell cycle distribution determined by flow cytometry. The data are 
indicated as relative percentage of total cell cycle (*P<0.05 compared to the scramble cells). 
 
Moreover, after p53 knockdown the cells showed a lower migratory ability and invasiveness 
then 3AB-OS and Scramble cells as shown by the data from wound healing, western blotting 
and qPCR  analyses. Indeed, wound healing assay (Fig.24 A and B), performed by Incucyte 
System, showed that 3AB-OS and Scramble cells  after the wound insult migrated faster than 
sh-p53 cells and after 16 hours only in 3AB-OS and Scramble cells the total repair of the 
scratch was observed.  
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Fig.24. Study of migration ability of 3AB-OS cells after p53R248W/P672R stable knockdown. A)Incucyte 
images that show the wound repair ability of 3AB-OS, Scramble and sh-p53 cells among 0 and 16 hours after the 
scratch; B) data graphed.  
As shown in figure 25A, mutant p53 stable knockdown determined a significant decrease of 
MMP2, VANGL1, CD44, SNAIL1, SNAIL2 and β-CATENIN mRNAs respect to the 
Scramble cells but not considerable differences in MMP9, ZEB1, ZEB2, VIM and N-
CADHERIN mRNAs. From western blotting analysis (FIG.25B) a great decrease of MMP2, 
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MMP9, CD44 and N-CADHERIN protein expression levels  were observed. A weird increase 
of VIM protein levels was evidenced and it could be explained by the presence of 
mechanisms like acetylation and detyrosination that usually stabilize this cytoskeletric protein 
(135). These data strongly confirmed that p53R248W/P72R plays an important role in the 
control of 3AB-OS cells migration and invasiveness. Recently, a few studies have shown that 
features of EMT (epithelial-mesenchymal transition) are closely associated with the 
signatures of CSCs, which could lead to tumor recurrence and drug resistance phenotype. It is 
proposed that while EMT may enhance the stemness of CSCS, MET (mesenchymal-epithelial 
transition) may attenuate the stemness of CSCs. Moreover, there are some evidences 
according to which EMT represents a mutant p53 gain of function (95). The data described 
above are consistent with the hypothesis that p53R248W/P72R controls EMT in order to 
maintain 3AB-OS cells stemness. Moreover, one of the most important aspect of EMT 
process is the involvement of WNT/beta-catenin pathway that shows an increase of beta-
catenin levels that translocates into the nuclei where it can exerts its co-transcriptional role. 
Immunofluorescence analyses (fig.25C), performed after mutant p53 stable knockdown, 
showed a clear β-catenin translocation from the nucleus to the cytoplasm reinforcing the 
hypothesis that this mutant leads the EMT in 3AB-OS stem cells.  
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Fig.25. 3AB-OS migration and invasive abilities after p53-R248W/P72R stable knockdown. A) Real-time 
PCR analysis of migration and invasivness genes after stable mutant 53 knockdown. Data represent the mean 
with standard deviation (n = 4); *P < 0.05 compared to Scramble 3AB-OS cells. B) Western blotting analysis of 
important invasiveness protein. C) The arrows indicate the localization of -catenin detected by using Alexa-
fluo secondary antibody.  
 
Thereafter, the expression levels of the main stemness markers such as KLF4, OCT4, 
NANOG, SOX2 and CD44 were evaluated by western blot (Fig.26A) and qPCR (Fig.26B) 
analyses. The results showed that they markedly decreased after p53R248W/P72R 
knockdown.  
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Fig.26. Stemness markers evaluation after p53-R248W/P72R stable knockdown. A) western blottin analysis 
of the main important stemness markers in 3AB-OS/shp53 cells compared with 3AB-OS Scramble cells. B)  
Real-time PCR analysis of important stemness genes after stable mutant 53 knockdown. Data represent the mean 
with standard deviation (n = 4); *P < 0.05 compared to Scramble 3AB-OS cells.  
 
Also the ability of 3AB-OS/sh-p53 to form colonies markedly decreased (fig. 27) respect to 
3AB-OS/Scramble. In particular, after ten days post seeding approximately 20 colonies with a 
mean diameter of 667,33 ± 43,09 µm were counted in silenced cells, respect to those counted 
on Scramble cells where  more than 40 colonies with a mean diameter of 1280,33 ± 145,02µm 
were counted.  
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Fig.27.Colonies forming ability of p53-R248W/P72R knockdown cells. A) A picture of 6-well plate after 
staining with with crystal violet of 3AB-OS/Scramble (on  the top) and 3AB-OS/sh-p53 (on the bottom) cells; B) 
phase contrast image (magnitude 2,5X) of  3AB-OS/Scramble (on  the top) and 3AB-OS/sh-p53 (on the bottom); 
Graphs summarizing C) plate efficiency (colonies/100 cells)   and D) relative colonies size. The data represent 
the mean with standard deviation (n = 4);*P < 0.05 and **P < 0.01 as compared with the Scramble cells. The 
data are representative of three independent experiments. 
 
To test whether after p53-R248W/P72R knockdown 3AB-OS cells lost their ability to form 
spheres in low attachment 300 cells for both conditions, Scramble and sh-p53 were seeded. 
After 10 days (Fig.28) silenced cells formed less and smaller spheres than the Scramble cells. 
In particular (fig.28B and C), 3AB-Os/sh-p53 cells formed approximately 30 spheres with a 
mean diameter of 1336 ± 42 µm respect to Scramble cells which formed more than 50 spheres 
with a mean diameter of 2300 ± 92,8 µm.  These data where confirmed by the total cell 
number obtained from the spheres of both cell conditions after 10 days post the seeding 
(Fig.28D). indeed, from 300 cells approximately 1,08x106 3AB-OS/Scramble cells and 
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2,3x105 3AB-OS/sh-p53 cells were counted. Moreover, the analysis of secondary and tertiary 
spheres showed the same trend of the primary (data not shown).  
 
Fig.28.Spheres forming ability of p53-R248W/P72R knockdown cells. A) Phase contrast images of primary 
sarcospheres formed from 3AB-OS/Scramble and 3AB-OS/sh-p53 cells after 10 days post seeding 
(magnitudo2,5X). Graphs summarizing number (B) and size (C) of spheres from 300 cells (days 10) and number 
of cells/sphere on day 10 (D). The data represent the mean with standard deviation (n = 4); *P < 0.05 as 
compared to Scramble cells. 
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DISCUSSION 
In about half of all human cancers, the tumor suppressor p53 protein is either lost or mutated 
and this often results in the expression of a transcriptionally inactive mutant p53 protein. Loss 
of p53 function influences cell cycle checkpoint controls, apoptosis, cell migration and 
invasion. Moreover, recent data suggests that expression of mutant p53 can acquire new 
oncogenic functions by which it drives tumor progression (136). P53 exerts its gain of 
function (GOF) increasing growth rate and motility, tumorigenicity metastatic progression 
and invasiveness and decreasing sensitivity to chemotherapeutic drugs. The GOF phenotypes 
can also be partially explained by a dominant-negative effect of mutant p53 on p73 and p63 
(137). P53 mutational status may determine the efficacy of many of the chemotherapeutic 
drugs. Overall, in OS patients, alterations of TP53 occurs in 50%–60% of cases and consist of 
point mutations (20%–30%, mostly missense mutations), gene rearrangements (10%–20%) 
and allelic loss (75%–80%) (138). p53 mutation status is useful as a valuable indicator for 
predicting chemoresistance in OS patients (139). Moreover, patients with Li-Fraumeni 
syndrome, a disorder characterized by a germline mutation at the p53 locus, have a 
significantly higher risk of developing OS (140). Previous analyses (130) of the TP53 gene 
status/role showed that, in comparison with parental MG63 cells (where TP53 gene is wild 
type, hyper methylated, rearranged and in single copy), 3AB-OS cells have TP53 gene 
mutated at the codons 248 and 72, unmethylated, rearranged and in multiple copies. 
Moreover, this mutant p53 (p53-R248W/P72R) is post-translationally stabilized and localized 
in to the nucleus. 
 In this thesis it has been shown that this mutant p53 is involved in promoting proliferation, 
invasiveness, resistance to apoptosis and stemness of 3AB-OS. Moreover, it has been 
demonstrated that p53-R248W/P72R transient and stable knockdown strongly reduces the 
growth and replication rate of 3AB-OS cells and concomitantly increases the expression of 
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negative regulators of cell cycle such as pRb, p130, p107, E2F4, GADD45, p21, p27 and 
CDKN2C, while decreases the expression of positive regulators such as CDK4, CDK6, 
CycD1, CycD2, CycB1, CycE1 and CycE2. These data were accompanied by a significant 
accumulation of cells in G0/G1 cell cycle phase with a simultaneous decrease in S and G2 
phases. The findings are in strong accordance with alteration of cell cycle genes, seen in up to 
80% of pediatric/adult OS patients, suggesting that the genetic lesions that deregulate G1/S 
cell cycle checkpoint could be a constant feature in the pathogenesis of OS (141, 142, 143). 
Another distinctive feature of mutant p53 is its ability to confer on cells an elevated resistance 
to a variety of apoptotic signals (97). Analyses of death receptors in OS samples and in OS 
cell lines, including MG63 cells, have demonstrated alterations within the DR4 gene, 
suggesting that these genetic alterations may be implicated in OS formation (144). Previously, 
it has been shown that 3AB-OS cells highly express a great number of genes required for 
inhibiting apoptosis (105) .and much lower levels of FAS and DR4 receptors than parental 
MG63 cells (118). Here it has been shown that in 3AB-OS cells p53-R248W/P72R transient 
knockdown significantly increased the expression of DR4 and DR5 receptors and the 
sensitivity to TRAIL-induced apoptosis. Moreover, this transient silencing induced a decrease 
in anti-apoptotic factors  such as Bcl-2 and Bcl-XL and an increase in pro-apoptotic factors 
such as Bax and Puma. Overall, these finding suggest that in 3AB-OS cells p53-R248W/P72R 
could hinder cell response to TRAIL-treatment. The stable knockdown of p53-R248W/P72R 
evidenced significant variations of expression levels of Bcl-2 family members with no 
measurable variations in Caspase-3 and its substrates. Moreover, the stable silencing of 
p53R248W/P72R in 3AB-OS CSCs seems to increase the amount of senescent cells respect to 
the Scramble cells. All these data demonstrated that the less number of cells after the 
knockdown was derived from the lower proliferation speed and the higher number of 
apoptotic and senescent cells respect to the Scramble condition.  
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Stemness acquisition is a key event in cancer development as it may induce progression, 
invasion, dissemination and metastasis. OS is a highly metastatic tumor and in patients with 
high-grade OS, increased MMPs expression was identified as prognostic marker for poor 
outcome (145,146). 
 Here, it has been shown that p53-R248W/P72R transient and stable knockdown causes a 
striking reduction of in vitro invasive ability of 3AB-OS cells with a decrease in the levels of 
invasion-related gene and protein such as MMP2, MMP9, ITGα5, ITGαV, Vangl1, CD44, 
Snail1, Snail2, N-cadherin and in transient silencing a concomitant marked increase of  E-
cadherin levels. This suggests that the oncogenic properties of p53-R248W/P72R could also 
enable 3AB-OS cells to promote invasion. The presence of OS stem-like cells has been 
reported in patient tumors (147) as well as in established human OS cell lines (148). 
Previously, it has been shown that 3AB-OS cells highly express a large panel of stemness-
related genes/proteins and that efficiently trans-differentiate in vitro into cells of all the three 
primary germ layers, whereas when 3AB-OS cells were engrafted in nude mice, they potently 
induced malignant tumors, although preserving multilineage commitment. Here, it has been 
shown that, after in vitro 3AB-OS differentiation, in each derived cell lineage (hepatocytic, 
adipocytic, neurogenic, osteocytic), p53-R248W/P72R was profoundly down-regulated and 
after p53-R248W/P72R transient and stable knockdown the expression of pluripotent markers 
such as Oct3/4, Nanog, Sox2, nucleostemin, CD133 and Klf4 were markedly lowered. These 
data suggested that p53-R248W/P72R might be responsible for 3AB-OS cells pluripotency 
and self-renewal. In fact, after stable silencing 3AB-OS cells decreased their ability to form 
colonies and spheres in vitro. Indeed, in sh-p53 cells these were less numerous, smaller, 
containing less cells respect to the control condition of Scramble cells. Moreover, these cells 
showed lowered invasion and migratory properties.in addition, the transient ectopic 
expression of p53-R248W/P72R in osteosarcoma MG63 cells (3AB-OS parental cells) 
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promoted cancer stem-like properties. In particular, when MG63 cells were transfected with 
pcDNA3.1-p53-R248W/P72R showed strong positivity for p53 that resulted to be nuclear. 
Moreover, MG63 cells expressing p53-R248W/P72R, compared with the cells expression the 
empty vector, showed a higher proliferative output, were able to form 2-fold sarcospheres and 
more numerous and larger colonies. In addition, these cells showed a higher migratory and 
invasive activity respect to the control vector cells and significant increase in the expression 
of stemness markers. 
 In conclusion, the findings that in 3AB-OS cells p53-R248W/P72Rknockdown profoundly 
changed the expression of genes/proteins correlated to stemness, proliferation, apoptosis and 
invasiveness, and that in MG63 parental cells, the ectopic expression of p53-R248W/ P72R 
promoted cancer stem-like properties, suggest that the GOF property of p53-R248W/P72R 
can be at the root of the dedifferentiation of MG63 cells into 3AB-OS CSCs. Thus 3AB-OS 
cells could provide a best-fit to understand p53-R248W/P72R properties and its potential 
involvement in osteosarcomagenesis 
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WORK IN PROGRESS 
The data described in this thesis, suggest that p53-R248W/P72R could be at the root of the 
dedifferentiation of osteosarcoma MG63 cell line in CSCs 3AB-OS cell line. For this reason I 
am aimed at evaluating the effects of the expression on this mutant-p53 in different  
osteosarcoma cell lines that are p53-null or p53-wild type. For my experiments I have chosen 
the cell lines SAOS-2 (p53-null because of a deletion), MG63 (p53-null because of the lack of 
gene expression) and U2-OS (p53-wild type). The production of SAOS-2, MG63 and U2-OS 
stable clones expressing the mutant p53- R248W/P72R is ongoing. I will also perform these 
experiments in the normal fibroblast cell line BJ-hTERT. I want to evaluate whether the stable 
ectopic expression of the mutant-p53 in these cell lines will induce the acquisition of stem-
like features. Once obtained these clones, I will test in them the presence of stemness features 
such as high proliferation rate, spheres formation, clonogenic growth, high migration and 
invasive ability, high expression of stemness markers. I expect that these experiments confirm 
the results that I have discussed in the thesis. Once demonstrated the hypothesis that p53-
R248W/P72R exerts its gain of function in 3AB-OS by keeping their stemness properties, the 
next step will be to find the possible mechanisms at the root of this gain of function. RNA-
sequencing analysis, where 3AB-OS/Scramble cells are compared with 3AB-OS/sh-p53 cells, 
is ongoing. I am waiting the bioinformatics elaboration of the data. It is well known that point 
mutations, called “hotspot” (such as R175, G245, R248, R249, R273 and R282) at the DNA-
binding domain (DBD) of wild type p53 affect its ability to bind the DNA and to exerts its 
tumor suppressor functions (149). Recent studies showed that these mutants can interact with 
the DNA binding sequences different from canonical wild type p53 consensus sequences 
using the C-terminal domain or recognizing particular DNA structures known as non-B DNA 
(150).  
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In order to understand if p53-R248W/P72R expressed in 3AB-OS cells, is able to bind the 
DNA, despite its hot spot mutation at the DBD, I performed a Chromatin Binding assay by 
which I could demonstrate that this mutant interacts with the DNA (Fig29). I will perform 
ChIP experiments in order to validate RNA-sequencing data with the aim of finding some 
known or unknown target involved in stemness or differentiation maintenance.  
                                 A 
                                 
                                  B 
 
Fig.29.Evaluation of p53 DNA-binding in 3AB-OS cells by Chromatin binding assay.   A) schematic 
description of the technique (151); B) western blotting analysis of the mutant p53 in the fractions. T, total 
fraction; S1, supernatant not chromatin-bound fraction; P1, pellet chromatin-bound fraction; S2, supernatant 
chromatin-bound; P2, pellet not chromatin-bound. 
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MATERIALS AND METHODS 
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Cell cultures 
Human osteosarcoma MG63 cells were acquired from Interlab Cell Line Collection (ICLC, 
Genova, Italy). The human 3AB-OS cancer stem cells have been produced in our laboratory 
(105) and patented (Pluripotent cancer stem cells: their preparation and use. Renza Vento and 
Riccardo Di Fiore, Patent Appln. No. FI2008A000238, December 11, 2008). Cell lines were 
cultured as monolayers in T-75 flask in Dulbecco's modified Eagle medium (DMEM), 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
100 U/ml penicillin and 50 μg/ml streptomycin (Euroclone, Pero, Italy) in a humidified 
atmosphere of 5% CO2 in air at 37 °C. When cells grew to approximately 80% confluence, 
they were sub-cultured or harvested using 0.025% trypsin–EDTA (Life Technologies Ltd, 
Monza, Italy).  
Morphological observation 
Cell morphology was evaluated using a Leica DM IRB inverted microscope (Leica 
Microsystems) and a Leica DMIL inverted microscope (Leica Microsystems) and images 
were captured computer-imaging systems(Leica DC300F and Leica EC3 cameras 
respectively) 
Immunofluorescence Staining for p53 
3AB-OS cells were fixed with 3.7% formaldehyde for 10 min at room temperature and 
permeabilized with 0.1% Triton® X-100 (all from Sigma) in phosphate-buffered saline (PBS) 
for 5 min. After washing with PBS, cells were incubated with anti-p53 primary antibody 
(diluted 1:100 in PBS + 1% BSA + 0.05% NaN3; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) at 4 °C, overnight. Cells were washed three times with PBS and incubated for 1 h at 
room temperature with Cy3-or Cy2-conjugated secondary antibody (diluted 1:100 in PBS + 
1% BSA + 0.05% NaN3; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). 
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Nuclei were counterstained with 2.5 μg/ml Hoechst 33342 (Sigma-Aldrich) for 10 min. After 
three washes, cells were examined on a Leica DMIRB inverted microscope equipped with 
fluorescence optics and suitable filters for DAPI, FITC and rhodamine detection; images were 
photographed and captured by a computer-imaging system (Leica DC300F camera and Adobe 
Photoshop for image analysis). 3AB-OS/sh-Scramble and 3AB-OS/sh-p53 were seeded in 
rounded coverslips placed in 24-well plate. When they were confluent to 80% they were 
washed with PBS and fixed and permeabilized as above. After washing some wells were 
incubated with anti-p53 primary antibody (diluted 1:100 in PBS + 1% BSA + 0.05% NaN3)  
and other with anti-b-catenin primary antibody (diluted 1:100 in PBS + 1% BSA + 0.05% 
NaN3)  at 4 °C, overnight. Cells were washed three times with PBS and incubated for 1 h at 
room temperature with Alexa Fluor® 488 Donkey Anti-Mouse IgG (H+L) and Alexa Fluor® 
647 Donkey Anti-Rabbit IgG (H+L) secondary antibodies respectively. At the end the cover 
slips were washed three times with PBS and one time in MilliQ sterile water and mounted by 
using ProLong® Gold Antifade Mountant with DAPI (Life Technologies). 
Transient down-regulation of p53 by short interfering RNA (siRNA) 
Cells were plated in a six-well plate format and cultured in DMEM medium, supplemented 
with 10% FBS, for 24 h to reach approximately 60–80% confluence. Specific siRNAs 
directed against p53, obtained by St Cruz Biotechnology as a pool of double-stranded RNA 
oligonucleotides, were transfected for 5 h into the cells at a final concentration of 50 nM, in 
the presence of 5 μl Metafectene Pro (Biontex, Martinsried/Planegg, GmBH, Munich, 
Germany) in a final volume of 1 ml serum free DMEM. At the end, the reaction was stopped 
replacing the culture medium with DMEM + 10% FBS. Cells were examined for p53 down-
regulation and other properties 24–72 h after transfection. siRNA, consisting in a scramble 
sequence, was used as a negative control. 
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Growth curve and cell viability assays 
Total Scra-siRNA and p53-siRNA cells number and viability were evaluated by Trypan blue 
exclusion counting. Briefly, cells were harvested every 24 h and resuspended in PBS. 
Aliquots of cell suspensions were diluted with 0.4% trypan blue (Sigma-Aldrich Srl, Milano, 
Italy), pipetted onto a hemocytometer and counted under a microscope at 100× magnification. 
Live cells excluded the dye, whereas dead cells admitted the dye intensely staining with 
trypan blue. The number of viable cells for each experimental condition was counted and 
represented on a linear graph. Doubling time(DT)was estimated by the following equation: 
DT = (t2 − t1) ln2 / lnX2 / X1, where X2 and X1 are the number of cells at t2 and t1. 
EdU in corporation assay 
EdU (5-ethynyl-2′-deoxyuridine) incorporation Scra-siRNA and p53-siRNA cells ability was  
evaluated by using the Click-iT™ EdU Alexa Fluor High-Throughput Imaging Assay kit 
(Invitrogen, Life Technologies), according to the manufacturer’s instructions. At the end 
nuclei were counterstained with 2.5 μg/ml Hoechst 33342 (Sigma-Aldrich), for 10 min and 
after three washes, cells were examined by fluorescence microscopy using filters for DAPI 
and FITC. The percentage of EdU-positive nuclei was determined by counting five random 
high-powered fields (400×). EdU (5-ethynyl-2′-deoxyuridine) incorporation 3AB-OS/sh-
Scramble and 3AB-OS/sh-p53 cells ability was  evaluated by using the Click-iT® EdU Alexa 
Fluor® 647 Flow Cytometry Assay Kit (Life Technologies), according to the manufacturer’s 
instructions. Cells were examined by flowcytometry  
MTS assay 
3AB-OS/sh-Scramble and 3AB-OS/sh-p53 were seeded in 96-well plate at a density of 2x103 
cells/well with 100 µl of medium. Wells containing only medium were used as blank. 20 µl of 
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MTS reagent were added to each well and the plate was incubated at 37°C for 1 hour. At the 
end the absorbance of the plate was read at 490nm. 
Cell cycle and proliferation analyses 
Cell cycle phase distribution was studied by flow cytometry of DNA content. For DNA 
staining, trypsinized cell suspensions were centrifuged, washed 3 times with PBS and 
resuspended at 1 ×106 cells/ml in PBS. Cells were mixed with cold absolute ethanol and 
stored for 1 h at 4 °C. After centrifugation, cells were rinsed 3 times in PBS, and the pellet 
was suspended in 1 ml of propidium iodide (PI) staining solution (3.8 mM sodium citrate, 25 
μg/ml PI, 10 μg/ml RNase A; Sigma-Aldrich Srl, Milano, Italy) and kept in the dark at 4 °C 
for 3 h prior to flow cytometry analysis. The proliferation index was calculated as the sum of 
cells in S and G2/M phases of cell cycle. 
β-Galactosidase assay  
To evaluate 3AB-OS senescence after p53-R248W/P72R Cell Signaling b-Galactosidase 
staining kit was used, according with the manufacturer’s instructions.  
Cell death assays 
Apoptotic morphology was studied in cells stained with Hoechst 33342 (Sigma-Aldrich). In 
particular, cells were stained with Hoechst 33342 (2.5 μg/ml medium) for 30 min at 37 °C, 
visualized by fluorescence microscopy using an appropriate filter for DAPI; images were 
photographed and captured. Cells were evaluated on the basis of their nuclear morphology, 
noting the presence of homogeneous chromatin, condensed chromatin, and fragmented nuclei. 
Apoptosis was also studied by flowcytometry of either DNA content or annexin V labelling.  
The DNA staining protocol has been described in “Cell cycle and proliferation analyses”. The 
proportion of cells giving fluorescence in the sub-G0/G1 peak of cell cycle was taken as a 
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measure of apoptosis. For annexin V labelling, trypsinized cell suspensionswere centrifuged, 
washed 3 times with PBS and resuspended in 1× annexin V binding buffer (BD Biosciences 
Pharmingen, San Diego, CA) at a concentration of 1 × 106 cells/ml. One hundred microliters 
of cell suspension was then incubated with 5μl of annexin V-FITC (BD Biosciences) and 5 
μL of PI for 15 min at a room temperature in the dark. Double labelled with annexin V and PI 
allows a distinction of early apoptotic (annexin V+/PI−) and late apoptotic/necrotic (annexin 
V+/PI+) cells. Flow cytometry analyses were performed by a COULTER EPICS XL flow 
cytometer (Beckman Coulter Srl, Cassina De Pecchi (MI), Italy) equipped with a single 
Argon ion laser (emission wavelength of 488 nm) and Expo 32 software. The green 
fluorescence was measured in the FL1 channel using a 515-nm BP filter, and the red 
fluorescence was measured in the FL3 channel using a 620-nm BP filter. At least 1 × 104 
cells per sample were analyzed and data were stored in list mode files. 
Measurement of mitochondrial transmembrane potential (Δψm) 
Mitochondrial membrane potential was measured by the cationic lipophilic fluorochrome 3,3-
dihexyloxacarbocyanine (DiOC6 Molecular Probes, Eugene, OR), which exclusively emits 
within the spectrum of green light. Loss in DiOC6 staining indicates disruption of the 
mitochondrial inner transmembrane potential (ΔΨm). Cells were incubated with 40 nM 
DiOC6 for 20 min at 37°C, washed twice with PBS and analysed by flow cytometry. The 
green fluorescence was measured as above described. 
In vitro Matrigel invasion assay 
Invasion assays were performed using 6-well invasion chamber system (BD Biosciences, 
Discovery Labware, Becton Dickinson, Buccinasco, Italy). Cells were trypsinized and 
counted with a hemocytometer using trypan blue, and viable cells were seeded in the upper 
chamber at 1 ×105 cells/well in serum-free DMEM. DMEM supplemented with 10% FBS 
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(used as a chemoattractant)was placed in the bottom well. Incubation was carried out for 48 h 
at 37 °C in humidified air with 5% CO2. Non-migratory cells in the upper chamber were then 
removed with a cotton-tip applicator. Migrated cells on the lower surface were stained with 
Hoechst 33342 (2.5 μg/ml; Sigma-Aldrich) for 10 min and then visualized under an inverted 
microscope. The number of migrating cells was determined by counting five high-powered 
fields (200×) on each membrane. Four independent experiments were performed in 
triplicate. 
Construction of expression vector expressing p53 mutation p53-R248W/P72R and 
transfection in MG63 cells. 
RNA from 3AB-OS cell line was isolated using TRI Reagent (Sigma- Aldrich), according to 
manufacturer's instructions. cDNA was amplified from 2 μg of RNA using M-MuLV reverse 
transcriptase (New England Biolabs, Euroclone, Pero, Italy). The following protocol was 
performed: RNA was incubated with dNTPs (Amersham Biosciences) and Random Examers 
(Promega Italia Srl, Milano, Italy) at 70 °C for 10 min and in ice for 1 min; then, after the 
addition of M-MuLV and the specific buffer, the incubation was performed at 42 °C for 1 h 
and at 90 °C for 10 min. The following primerswere used to amplified TP53 (≈1.2 kb): 
forward (BamHI restriction site-containing) 5′-
CGTAGGATCCAGCCATGGAGGAGCCGCAG-3′ and reverse (XhoI restriction site-
containig) 5′-CGGATCTCGAGCAATTCAGTCTGAGTCAGGCC-3′. For PCR 
amplification with Phusion Taq polymerase (New England Biolabs), the following protocol 
was performed: 98 °C for 2 min; 12 cycles at 98 °C for 10 s, 63 °C for 20 s and 72 °C for 30 
s; 18 cycles at 98 °C for 10 s and 72 °C for 30 s; a final extension at 72 °C for 7 min. The 
amplified product was resolved by agarose gel electrophoresis (1% agarose and 0.5 μg/ml 
ethidium bromide; Sigma-Aldrich) and the band was extracted using Wizard SV Gel and PCR 
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Clean-up system (Promega Italia Srl). PCR product and pcDNA 3.1 vector (Invitrogen) were 
digested for 2 h at 37 °C with BamHI-HF and XhoI (New England Biolabs), resolved by 
agarose gel electrophoresis and extracted. Vector dephosphorylation and ligation reactions 
were performed using the Rapid Dephosphorylation and Ligation kit (Roche, Milano, Italy) 
according to manufacturer's instructions. The ligation mixture was transformed into calcium 
chloride-competent DH5α cells (Invitrogen). Plasmids after BamHI–XhoI digestion that 
showed the presence of a 1.2-kb insert were validated by sequencing (Ceinge Sequencing 
Service, Ceinge, Napoli, Italy). MG63 cells were plated in 6-well dishes until they reached 
90% confluence and then transfected with p53-R248W/P72R-pcDNA 3.1 or empty vector, as 
a control, using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. 
Two days after transfections, the cells were transferred in 100 mm dishes in selective medium 
containing 300 μg/ml G418 (Gibco, Life Technologies Ltd, Monza, Italy); the medium was 
replaced every 3–4 days. A plate of untrasfected cells was used as a control for the selection. 
Construction of expression vector expressing a sh-p53 and transduction in 3AB-OS cells. 
For transduction experiments shScramble-pLKO-1 puro and shp53-pLKO.1 puro vectors 
were used to construct 3AB-OS/sh-Scramble and 3AB-OS/sh-p53 cells respectively .  
2x106 HEK-293FT cells were seeded in 10cm dish.  
The day after the packaging was prepared as follow:  
-7µg of shp53-PLKO.1 puro vector 
-6µg of psPAX8-plasmid  
- 5µg of CMV-VSVG plasmid 
H2O (to a final volume of 450µl) 
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To these 450µl, 50µl of CaCl2 (2,5M) were added. After 10-20 minutes 500µl of HBS(2X) 
vortexing or making bubbles. The final volume of this mix is 1ml. After changing the medium 
to HEK-293FT putting 9ml of fresh DMEM, the mix above was added. The cells were 
incubated at 37°C. After 8-15 hours the medium was changed (using the medium used for the 
cells-DMEM). After approximately 36 hour the virus were harvest; polybrene (8µg/ml) was 
added to the medium that was filtered through a 0,45µm filter on a syringe and then added to 
3AB-OS (incubated at 37°C). After 8-15 hours the medium was changed and after 48 hours 
the cells were put in selection with puromicyn  
Sarcosphere formation assay 
MG63 cells transfected with pcDNA3.1-p53-R248W/P72R or empty pcDNA3.1 vector were 
seeded in 6-well ultra-low attachment plates (Corning Costar, Euroclone) at a density of 500 
cells/well with 3 ml stem cell medium consisting of DMEM/F12 (Gibco), B27 (1× Gibco), 
recombinant human epidermal growth factor (rhEGF, 20 ng/ml; Sigma-Aldrich) and basic 
fibroblast growth factor (bFGF, 20 ng/ml; Sigma-Aldrich). The stem cell medium was 
changed every 3 days, and cells were observed every day by microscopy. After the primary 
spheres reached approximately ≥50 μm in diameter (determined using the ImageJ software), 
they were collected by gentle centrifugation (800 rpm), enzymatically dissociated (10 min at 
37 °C in 0.05% trypsin–EDTA; Life Technologies Ltd) to single cells and replanted into 6-
well ultra-low attachment plates with 500 cells/well and cultured with stem cell medium to 
generate spheres of the next generation. For the 3AB-OS/sh-Scramble and 3AB-OS/sh-p53 
cells the same protocols was followed but the cells were seeded at a density of 500 cells/well. 
Colony formation assay 
MG63 cells transfected with pcDNA3.1-p53-R248W/P72R or empty pcDNA3.1 vector were 
seeded in 6-well plates at a density of 100 cells/well with 3 ml culture medium and incubated 
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for 10 days. The medium was changed every 3 days, and cells were observed every day by 
microscopy. On the tenth day, media was removed from the wells and washed once with ice-
cold PBS. The colonies were fixed with 50% EtOH and stained with 1% methylene blue 
(Sigma-Aldrich) for 10 min. After three washes with PBS, the colonies consisting of N50 
cells were counted using microscopy. Colony size was determined by measuring the area with 
the ImageJ software. For the 3AB-OS/sh-Scramble and 3AB-OS/sh-p53 cells the same 
protocol was followed but at the end the cells were fixed with 4% of formaldeide and they 
were  stained with 0,1% of crystal violet. 
Scratch/wound-healing assay 
To analyze cell migration by wound healing, confluent monolayers of MG63 cells transfected 
with pcDNA3.1-p53-R248W/P72R or empty pcDNA3.1 vector and cultured in 6-well plates 
were scratched with a 200-μl pipette tip to generate the wound. One hour before scratching, 
the medium was replaced with medium containing 0.1% FBS to minimize the cell 
proliferation. Phase-contrast photographs of the same region were taken with the same 
magnification (100×) at 0, 8 and 24 h post-wounding. The extent of wound closure was 
determined by measuring with the ImageJ software the area of cells that migrated into the 
wound and then dividing by the total area of wound. For the 3AB-OS/sh-Scramble and 3AB-
OS/sh-p53 cells the Incucyte/wound-healing system was used and the cells were monitored 
among 0 and 16 hours post scratch insult. The Incucyte-system software measured the wound 
closure.  
Flow cytometry analysis of CD133, ABCG2 and p53 expression 
Cells were detached using 0.025% trypsin–EDTA in PBS, counted and washed in 0.1% BSA 
in PBS at 4 °C. At least 500,000 cells (in 100 μl PBS/ 0.5% BSA) were incubated with 
fluorescent-labelled monoclonal antibodies or respective isotype controls (1/10 diluted 4 °C 
for 30 min in the dark). After washing steps, the labelled cells were analyzed by flow 
75 
 
cytometry using COULTER EPICS XL (Beckman-Coulter Srl) and Expo 32 software. The 
antibodies used were mouse anti-human CD133/2 PE conjugated (Miltenyi Biotec S.r.l., 
Bologna, Italy), mouse anti-human ABCG2 nonconjugated (Santa Cruz Biotechnology) and 
mouse anti-human p53 nonconjugated (Santa Cruz Biotechnology). For indirect labelling, 
cellswere incubatedwith a compatible secondary antibody FITC conjugated (Santa Cruz 
Biotechnology, Inc.). For intracellular staining of CD133, ABCG2 and p53, cells were 
processed using the Caltag Fix & Perm Kit (Invitrogen) following the manufacturer's 
guidelines. The green fluorescence was measured as described in the Cell death assays 
section, and the phycoerythrin fluorescence was measured in the FL2 channel using a 575-nm 
BP filter. At least 1 × 104 cells per sample were analyzed, and data were stored in list mode 
files. The expression of cell markers was determined by comparison with isotype control. 
RNA extraction and real-time RT-PCR 
RNA was extracted by Trizol reagent (Life Technologies Ltd, Monza, Italy); a DNase I 
treatment step was included. One microgram of total RNA was reverse transcribed in a final 
volume of 20 μl reverse transcription (RT) by using a Super-Script First-Strand Synthesis kit 
for RT-PCR (Life Technologies Ltd) according to the manufacturer's instructions. The 
resulting cDNAs were used for quantitative analysis by real-time PCR (qPCR) using the 
primers reported in following table and the Power SYBR Green PCR Master Mix (Applied 
Biosystem, Warrington, UK). Reactions were performed in 96-well plates according to 
manufacturer's instructions, using Applied Biosystems StepOneTM instrument. levels were 
determined using the 2−ΔΔCt method and normalized to endogenous β-actin  and GAPDH 
levels. The primer sequences used are listed in the following table. 
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
CD133 ttggctcagactggtaaatccc ataggaaggactcgttgctggt 
OCT4 ctgggggttctatttggga ctggttcgctttctctttcg 
Nanog gcaagaactctccaacatcctga gccacctcttagatttcattctctg 
Sox2 cacccacagcaaatgacag tacaaggtccattcccccg 
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Nucleostemin (NS) gggaagataaccaagcgtgtg cctccaagaagtttccaaagg 
E-Cadherin gcaaattcctgccattctgg cgaagaaacagcaagagcagc 
VIM agagaggaagccgaaaacac tgttcctgaatctgagcctg 
N-Cadherin tcaacttgccagaaaactccag ccgcagtgaaaggtttttatctct 
β-catenin agtgctgaaggtgctatctg tgaaagattcctgagagtcc 
MMP-9 cctggagacctgagaaccaatc gatttcgactctccacgcatc 
MMP-2 acgaagacccacaggaggag tagccagtcggatttgatgc 
ITGA5 cccagacttctttggctctg gcaagatctgagccttgtcc 
ITGAV ttgttgctactggctgttttg tccctttcttgttcttcttgag 
RB1 caccaatacctcacattcctc ttctcagaagtcccgaatg 
p107 gatgctacaaaaacacctgactg gctgctgggaaatgcggc 
RB2 tacacgctggagggaaat ttccactgtccctttgcttac 
E2F1 gacctgctgctcttcgccac tttcacaccttttcctggatg 
E2F4 ggacggcgtgcttgacctc cccttccactggatgctgt 
p21 ctgtcttgtacccttgtgcctc aatctgtcatgctggtctgcc 
p27 ctgcaaccgacgattcttct gcttcttgggcgtctgctc 
GADD45 agaccccggacctgcact ccggcaaaaacaaataagttgact 
CDK4 cggggctggcgtgagggtc actgtggggatcacgggc 
Bcl-2 ggataacggaggctgggat ggcaggcatgttgacttcac 
Bcl-xl tccttgtctacgctttccac ggtcgcattgtggccttt 
Bax cagaggcggggggc gtccacggcggcaatcatc 
Puma acgacctcaacgcacagtacg tcccatgatgagattgtacaggac 
α-actin ggacttcgagcaagagatgg agcactgtgttggcgtacag 
P53 tagtgtggtggtgccctatg cccatgcaggaactgttacac 
Cyclin D1 ggcggaggagaacaaacaga ctcctcaggttcaggccttg 
Cyclin D2 gctggaggtctgtgaggaac agttgcagatgggacttcgg 
Cyclin E1 atacttgctgcttcggcctt tcagttttgagctccccgtc 
Cyclin E2 gcccagataatccaggcca acaggtggccaacaattcct 
CDKN2C caggactctccccatctcca tcaggctttctgctgtaggc 
VANGL1 agtaaagaagcggaaagcaaggc ctggagacgctgaatgtggatg 
CD44 acagacagaatccctgctaccac tgcctcttggttgctgtctcag 
SNAIL1 gctgcaggactctaatccaga atctccggaggtgggatg 
SNAIL2 tggttgcttcaaggacacat gttgcagtgagggcaagaa 
ZEB1 gccaacagaccagacagtgtt tttcttgcccttcctttctg 
ZEB2 aagccagggacagatcagc gccacactctgtgcattt 
KLF-4 tgtgactatgcaggctgtg aggtttctcgcctgtgtg 
 
Western blotting analysis 
Cells were washed in PBS and incubated on ice-cold lysis buffer (RIPA buffer 50 μl/106 
cells) containing protease inhibitor cocktail for 30 min and sonicated three times for 10 s. 
Equivalent amounts of proteins (20-40 μg) were separated by SDS– polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad/Amersham) for 
detection with primary antibodies and the appropriate peroxidase–conjugated secondary 
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antibodies. Immunoreactive signals were detected using enhanced chemiluminescence (ECL) 
reagents (Bio-Rad/Pierce). The correct protein loading was confirmed by stripping the 
immunoblot and reprobing with primary antibody for actin (diluted 1:500; Sigma) and 
GAPDH (1:10000;Santa Cruz). To detect the protein expression levels during transient p53-
knockdowm experiments Chemi Doc XRS (Bio-Rad) system was used while Amersham® 
Hyperfilm® ECL™ and MP Autoradiography Films,GE Healthcare were used to detect the 
expression levels of the proteins analyzed during stable p53-knockdown.Quantification was 
performed using Quantity One software, and the data (relative density normalized to actin) 
were expressed as mean ± SD of four experiments. The primary antibodies used during 
transient p53 silencing are listed below. 
ANTIBODY  HOST ORIGIN DILUTION COMPANY PRODUCT NUMBER 
CD133 Rabbit 1:300 Abgent AP2010b 
Oct3/4 Mouse 1:300 Santa Cruz Biotechnology sc-5279 
Nanog Goat 1:500 Santa Cruz Biotechnology sc-30331 
Sox2 Rabbit 1:300 Santa Cruz Biotechnology sc-20088 
Nucleostemin (NS) Goat 1:500  Santa Cruz Biotechnology sc-46218 
mmp2 Rabbit 1:300 Santa Cruz Biotechnology sc-10736 
mmp9 Rabbit 1:1000 Cell Signaling 3852S 
Itga5 Rabbit 1:300 Santa Cruz Biotechnology sc-10729 
Itgav Rabbit 1:300 Santa Cruz Biotechnology sc-10719 
E-chaderin Mouse 1:300 Santa Cruz Biotechnology sc-1500 
Vimentin Mouse 1:500 Santa Cruz Biotechnology sc-73259 
N-chaderin Mouse 1:500 Santa Cruz Biotechnology sc-8424 
-catenin Mouse 1:500  Santa Cruz Biotechnology sc-7963 
pRb Mouse 1:500  Santa Cruz Biotechnology sc-102 
p107 Rabbit 1:200 Santa Cruz Biotechnology sc-318 
p130 Mouse 1:300 Santa Cruz Biotechnology sc-9963 
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E2f1 Rabbit 1:500 Santa Cruz Biotechnology sc-193 
E2f4 Rabbit 1:300 Santa Cruz Biotechnology sc-866 
p53 Mouse 1:500  Santa Cruz Biotechnology sc-126 
p21 Rabbit 1:200 Santa Cruz Biotechnology sc-397 
p27 Rabbit 1:200 Santa Cruz Biotechnology sc-1641 
Gadd45 Mouse 1:300 Santa Cruz Biotechnology sc-6850 
Cdk4 Rabbit 1:200 Santa Cruz Biotechnology sc-601 
Bcl-2 Mouse 1:500  Santa Cruz Biotechnology sc-509 
Bcl-XL Mouse 1:500 Santa Cruz Biotechnology sc-8392 
Bax Mouse 1:500  Santa Cruz Biotechnology sc-7480 
Puma Mouse  1:300 Santa Cruz Biotechnology sc-377015 
DR4 Rabbit 1:500  ProSci Incorporeted 1139 
DR5 Rabbit 1:500  ProSci Incorporeted 2019 
FAS Mouse 1:300 Santa Cruz Biotechnology sc-8009 
actin Rabbit 1:500 Sigma A5060 
 
The primary antibodies used during stable p53 silencing are listed below. 
ANTIBODY  HOST ORIGIN DILUTION COMPANY PRODUCT NUMBER 
p53 Mouse 1:1000 Santa Cruz Biotechnology sc-126 
CyclinD1 Mouse 1:1000 Santa Cruz Biotechnology sc-20044 
CyclinB1 Mouse 1:1000 Cell Signaling 4135 
p21 Mouse 1:1000 Santa Cruz Biotechnology sc-6246 
p27 Rabbit 1:1000 Cell Signaling 2552 
CDK6 Rabbit 1:1000 Santa Cruz Biotechnology sc-177 
Bax Mouse 1:1000 Santa Cruz Biotechnology sc-7480 
Bad Rabbit 1:1000 Cell Signaling 9292 
Bcl-2 Mouse 1:1000 Santa Cruz Biotechnology sc-7382 
Bcl-XL Rabbit 1:1000 Cell Signaling 2762 
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LaminB1 Mouse 1:500 Santa Cruz Biotechnology sc-377000 
PARP Rabbit 1:1000 Cell Signaling 9542 
Caspase-3 Rabbit 1:1000 Cell Signaling 9662 
MMP2 Rabbit 1:1000 Abcam ab80737 
MMP9 Rabbit 1:1000 Abcam ab38898 
N-cadherin Rabbit 1:1000 Abcam ab18203 
Vimentin Mouse 1:1000 Santa Cruz Biotechnology sc-373717 
CD44 Rabbit 1:100 Cell Signaling 3578 
Oct4 Rabbit 1:1000 Abcam ab19857 
Nanog Rabbit 1:200 Abcam ab21603 
Sox2 Mouse 1:500 R&D system MAB2018 
Klf4 Rabbit 1:100 Santa Cruz Biotechnology sc-2069 
GAPDH Rabbit 1:10000 Santa Cruz Biotechnology sc-25778 
 
Chromatin binding assay 
The ability of p53-R248W/P72R to bind the DNA was evaluated according to the protocol 
described by LIano M. (151). 
Statistical Analysis 
Data, represented as mean ± SD, were analyzed using the 2-tailed Student t-test using 
Microsoft Excel. Differences were considered significant when P < 0.05. 
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